<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17856" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Rheumatoid Arthritis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Chauhan</surname>
            <given-names>Krati</given-names>
          </name>
          <aff>Southern Illinois University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jandu</surname>
            <given-names>Jagmohan S.</given-names>
          </name>
          <aff>University of Nevada Reno, School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Brent</surname>
            <given-names>Lawrence H.</given-names>
          </name>
          <aff>Temple University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Al-Dhahir</surname>
            <given-names>Mohammed A.</given-names>
          </name>
          <aff>Strong Memorial Hospital/ University of Rochester / visiting physician</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Krati Chauhan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jagmohan Jandu declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Lawrence Brent declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mohammed Al-Dhahir declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>25</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17856.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by inflammatory arthritis and extra-articular involvement. It is a chronic inflammatory disorder caused in many cases by the interaction between genes and environmental factors, including tobacco, that primarily involves synovial joints. It typically starts in small peripheral joints, is usually symmetric, and progresses to involve proximal joints if left untreated. Joint inflammation over time leads to the destruction of the joint with loss of cartilage and bone erosions. RA with a symptom duration of fewer than six months is defined as early RA, and when the symptoms have been present for more than six months, it is defined as established RA. RA, if untreated, is a progressive disease with morbidity and increased mortality. This activity describes the evaluation and management of rheumatoid arthritis and reviews the role of the interprofessional team in improving care for patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the comorbid conditions associated with rheumatoid arthritis.</p></list-item><list-item><p>Summarize the pathophysiology of rheumatoid arthritis.</p></list-item><list-item><p>Outline the use of rheumatoid factor and anti-citrullinated protein antibodies in evaluating rheumatoid arthritis.</p></list-item><list-item><p>Review the importance of improving care coordination among the interprofessional team to improve outcomes for those affected with rheumatoid arthritis.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17856&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17856">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17856.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Rheumatoid arthritis (RA)&#x000a0;is a systemic autoimmune disease characterized by inflammatory arthritis and extra-articular involvement. It is a chronic inflammatory disorder caused in many cases by the interaction between genes and environmental factors, including tobacco, that primarily involves synovial joints.<xref ref-type="bibr" rid="article-17856.r1">[1]</xref> It typically starts in small peripheral joints, is usually symmetric, and progresses to involve proximal joints if left untreated.<xref ref-type="bibr" rid="article-17856.r2">[2]</xref><xref ref-type="bibr" rid="article-17856.r3">[3]</xref><xref ref-type="bibr" rid="article-17856.r4">[4]</xref>&#x000a0;Joint inflammation over time leads to the destruction of the joint with loss of cartilage and bone erosions. RA with a symptom duration&#x000a0;of fewer&#x000a0;than six months is defined as early RA, and when the symptoms have been&#x000a0;present for more than six months, it is defined as established RA.<xref ref-type="bibr" rid="article-17856.r3">[3]</xref>&#x000a0;RA, if untreated, is a progressive disease with morbidity and increased mortality.<xref ref-type="bibr" rid="article-17856.r5">[5]</xref></p>
        <p>There is no pathognomonic laboratory test for rheumatoid arthritis, which makes the diagnosis of this disease challenging in the early stages. A comprehensive clinical approach is required to make the diagnosis and prevent debilitating joint damage.<xref ref-type="bibr" rid="article-17856.r2">[2]</xref><xref ref-type="bibr" rid="article-17856.r3">[3]</xref>&#x000a0;The treatment of patients with rheumatoid arthritis requires both pharmacological and non-pharmacological therapy. Today, the standard of care is early treatment with disease-modifying anti-rheumatic drugs. Despite treatment, many patients progress to disability and suffer significant morbidity over time. A comprehensive pharmacological and non-pharmacological treatment (physical therapy, counseling, and patient education) is required to improve clinical outcomes.<xref ref-type="bibr" rid="article-17856.r4">[4]</xref></p>
      </sec>
      <sec id="article-17856.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The etiology of RA has a significant basis in genetics. It is thought to result from the interaction between patients' genotypes&#x000a0;and environmental factors. In a nationwide study of 91 monozygotic (MZ) and 112 dizygotic (DZ) twin pairs in the United Kingdom, the overall MZ concordance rate was 15%, and in dizygotic twins, 5%.<xref ref-type="bibr" rid="article-17856.r6">[6]</xref> The heritability of rheumatoid arthritis is approximately 40% to 65% for seropositive rheumatoid arthritis and 20% for seronegative rheumatoid arthritis.<xref ref-type="bibr" rid="article-17856.r7">[7]</xref>&#x000a0;The risk of developing rheumatoid arthritis has been associated with HLA-DRB1 alleles: <italic toggle="yes">HLA-DRB1*04</italic>, <italic toggle="yes">HLA-DRB1*01</italic>, and <italic toggle="yes">HLA-DRB1*10</italic>. These HLA-DRB1 alleles contain a stretch of a conserved sequence of 5 amino acids referred to as the "shared epitope" (SE) in the third hypervariable region of their DRB1 chain, which has been associated with the risk of developing RA.<xref ref-type="bibr" rid="article-17856.r8">[8]</xref><xref ref-type="bibr" rid="article-17856.r9">[9]</xref><xref ref-type="bibr" rid="article-17856.r10">[10]</xref><xref ref-type="bibr" rid="article-17856.r11">[11]</xref></p>
        <p>Polymorphisms in other genes are associated with RA, including <italic toggle="yes">PAD14</italic>,<italic toggle="yes"> PTPN22</italic>,&#x000a0;<italic toggle="yes">CTLA4</italic>,&#x000a0;<italic toggle="yes">IL-2RA</italic>, <italic toggle="yes">STAT4</italic>, <italic toggle="yes">TRAF1</italic>, <italic toggle="yes">CCR6</italic>, and&#x000a0;<italic toggle="yes">IRF5</italic>.<xref ref-type="bibr" rid="article-17856.r12">[12]</xref><xref ref-type="bibr" rid="article-17856.r13">[13]</xref><xref ref-type="bibr" rid="article-17856.r14">[14]</xref>&#x000a0;Single nucleotide polymorphism (SNP) in <italic toggle="yes">PSORS1C1</italic>, <italic toggle="yes">PTPN22</italic>, and <italic toggle="yes">MIR146A</italic> genes are associated with severe disease.<xref ref-type="bibr" rid="article-17856.r15">[15]</xref>&#x000a0;Some genetic polymorphisms are associated with RA in different ethnic groups.<xref ref-type="bibr" rid="article-17856.r13">[13]</xref><xref ref-type="bibr" rid="article-17856.r15">[15]</xref></p>
        <p>The term epigenetics refers to heritable changes without altering the DNA sequence. These changes may be present in chromatin or the DNA. These include DNA methylation, histone modification, and non-coding RNA-mediated regulation. RA-FLS (fibroblast-like synoviocytes) overexpress tyrosine phosphatase SHP-2, coded by gene PTPN11, compared to synoviocytes from osteoarthritis (OA) patients, promoting the invasive nature of RA-FLS. The enhancer region of the PTPN11 intron contained two hypermethylated sites, resulting in abnormal epigenetic regulation of the gene and alteration of the function of RA-FLS.<xref ref-type="bibr" rid="article-17856.r16">[16]</xref></p>
        <p>Cigarette smoking is the strongest environmental risk factor associated with rheumatoid arthritis. Studies have shown in anti-citrullinated protein antibody (anti-CCP) positive individuals, there is an interaction between the shared epitope (SE) and&#x000a0;smoking that increases the risk of RA.<xref ref-type="bibr" rid="article-17856.r17">[17]</xref><xref ref-type="bibr" rid="article-17856.r18">[18]</xref><xref ref-type="bibr" rid="article-17856.r19">[19]</xref><xref ref-type="bibr" rid="article-17856.r20">[20]</xref><xref ref-type="bibr" rid="article-17856.r21">[21]</xref><xref ref-type="bibr" rid="article-17856.r22">[22]</xref><xref ref-type="bibr" rid="article-17856.r23">[23]</xref>&#x000a0;</p>
        <p>Other environmental triggers may play a role as a trigger for RA, which is more closely associated with seropositive RA. These include silica, asbestos, textile dust, and&#x000a0;<italic toggle="yes">P gingivalis.</italic><xref ref-type="bibr" rid="article-17856.r1">[1]</xref><bold>&#x000a0;</bold>This suggests that external exposure to various antigens in parts of the host distant from the joints then triggers an autoimmune inflammatory response in the joints. These distant locations include the lungs, oropharynx, and GI tract.<xref ref-type="bibr" rid="article-17856.r1">[1]</xref>&#x000a0;Changes in the composition and function of the intestinal microbiome have been related to rheumatoid arthritis as well. The composition of the gut microbiome becomes altered in patients with rheumatoid arthritis (dysbiosis), where rheumatoid arthritis patients have decreased gut microbiome diversity compared with healthy individuals. There is an increase in these genera:&#x000a0;<italic toggle="yes">Actinobacteria, Collinsella, Eggerthalla, and Faecalibacterium</italic>. <italic toggle="yes">Collinsella </italic>alters gut mucosal permeability and has been related to increased rheumatoid arthritis disease severity.<xref ref-type="bibr" rid="article-17856.r23">[23]</xref></p>
        <p>
<bold>Genes Associated with Increased Risk of RA</bold>
<xref ref-type="bibr" rid="article-17856.r12">[12]</xref>
<xref ref-type="bibr" rid="article-17856.r13">[13]</xref>
</p>
        <p>Gene&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; Gene product</p>
        <table-wrap id="article-17856.table0" position="float" orientation="portrait">
          <table style="height: 355px;" border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr style="height: 13px;">
                <td style="width: 567.5px; height: 13px;" rowspan="1" colspan="1">
<italic toggle="yes">HLA-DRB1</italic>
</td>
                <td style="width: 567.5px; height: 13px;" rowspan="1" colspan="1">HLA Class II BRB1 beta chain: antigen presentation</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 567.5px; height: 13px;" rowspan="1" colspan="1">
<italic toggle="yes">&#x000a0;PADI4</italic>
</td>
                <td style="width: 567.5px; height: 13px;" rowspan="1" colspan="1">Peptidyl Arginine Deiminase 4: an enzyme that converts arginine to citrulline</td>
              </tr>
              <tr style="height: 39px;">
                <td style="width: 567.5px; height: 39px;" rowspan="1" colspan="1">
<italic toggle="yes">&#x000a0;PTPN22</italic>
</td>
                <td style="width: 567.5px; height: 39px;" rowspan="1" colspan="1">Protein Tyrosine Phosphatase Non-Receptor Type 22:&#x000a0;non-receptor class 4 subfamily of the protein-tyrosine phosphatase family involved in T cell signaling, a negative regulator of T cell receptor signaling.</td>
              </tr>
              <tr style="height: 26px;">
                <td style="width: 567.5px; height: 26px;" rowspan="1" colspan="1">
<italic toggle="yes">&#x000a0;CTLA4</italic>
</td>
                <td style="width: 567.5px; height: 26px;" rowspan="1" colspan="1">Cytotoxic T-Lymphocyte Associated Protein 4: engagement of this surface protein transmits an inhibitory signal to T cells</td>
              </tr>
              <tr style="height: 26px;">
                <td style="width: 567.5px; height: 26px;" rowspan="1" colspan="1">
<italic toggle="yes">&#x000a0;IL2RA</italic>
</td>
                <td style="width: 567.5px; height: 26px;" rowspan="1" colspan="1">&#x000a0;Interleukin 2 Receptor Subunit Alpha: part of the IL2 receptor protein involved in T cell activation (and also other lymphoid cells)</td>
              </tr>
              <tr style="height: 26px;">
                <td style="width: 567.5px; height: 26px;" rowspan="1" colspan="1">
<italic toggle="yes">&#x000a0;STAT4</italic>
</td>
                <td style="width: 567.5px; height: 26px;" rowspan="1" colspan="1">Signal Transducer And Activator Of Transcription 4: a member of the STAT family of transcription factors involved in signal transduction of INF-gamma and IL-12 stimulation</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 567.5px; height: 13px;" rowspan="1" colspan="1">
<italic toggle="yes">TRAF1</italic>
</td>
                <td style="width: 567.5px; height: 13px;" rowspan="1" colspan="1">TNF Receptor Associated Factor 1: TRAF proteins associate with and mediate the signal transduction from various receptors of the TNFR</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 567.5px; height: 13px;" rowspan="1" colspan="1">
<italic toggle="yes">CCR6</italic>
</td>
                <td style="width: 567.5px; height: 13px;" rowspan="1" colspan="1">C-C Motif Chemokine Receptor 6: a member of the beta chemokine receptor family, important in B cell maturation</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 567.5px; height: 13px;" rowspan="1" colspan="1">
<italic toggle="yes">IRF5</italic>
</td>
                <td style="width: 567.5px; height: 13px;" rowspan="1" colspan="1">Interferon Regulatory Factor 5: a member of the interferon regulatory factor (IRF) family of transcription factors involved in type 1 interferon signal transduction</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>
<bold>Environmental Factors Associated with an Increased Risk of Developing RA</bold>
<xref ref-type="bibr" rid="article-17856.r1">[1]</xref>
</p>
        <table-wrap id="article-17856.table1" position="float" orientation="portrait">
          <table style="height: 277px;" border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr>
                <td style="width: 262.75px;" rowspan="1" colspan="1">Exposure</td>
                <td style="width: 262.75px;" rowspan="1" colspan="1">RA overall</td>
                <td style="width: 262.75px;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;Seropositive RA</td>
                <td style="width: 262.75px;" rowspan="1" colspan="1">Seronegative RA</td>
              </tr>
              <tr>
                <td style="width: 262.75px;" rowspan="1" colspan="1">Smoking</td>
                <td style="width: 262.75px;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;+</td>
                <td style="width: 262.75px;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;+</td>
                <td style="width: 262.75px;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;+/-</td>
              </tr>
              <tr>
                <td style="width: 262.75px;" rowspan="1" colspan="1">Silica</td>
                <td style="width: 262.75px;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;+</td>
                <td style="width: 262.75px;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;+</td>
                <td style="width: 262.75px;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;+/-</td>
              </tr>
              <tr>
                <td style="width: 262.75px;" rowspan="1" colspan="1">Asbestos</td>
                <td style="width: 262.75px;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;+</td>
                <td style="width: 262.75px;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;+</td>
                <td style="width: 262.75px;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; +</td>
              </tr>
              <tr>
                <td style="width: 262.75px;" rowspan="1" colspan="1">Textile dust</td>
                <td style="width: 262.75px;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;+</td>
                <td style="width: 262.75px;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;+</td>
                <td style="width: 262.75px;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; +</td>
              </tr>
              <tr>
                <td style="width: 262.75px;" rowspan="1" colspan="1">
<italic toggle="yes">P. gingivalis</italic>
</td>
                <td style="width: 262.75px;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;+</td>
                <td style="width: 262.75px;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;+</td>
                <td style="width: 262.75px;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;?</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="article-17856.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The worldwide prevalence of RA in the Global Burden of Disease 2010 Study is about 0.24%.<xref ref-type="bibr" rid="article-17856.r24">[24]</xref>&#x000a0;The prevalence of RA is higher in Western and Northern Europe, North America, and other regions with people of European descent, such as Australia. The prevalence is lower in Central and South America and even lower in East Asia and Africa.<xref ref-type="bibr" rid="article-17856.r24">[24]</xref> The annual incidence of RA in the United States and other western nations of northern Europe is about 40 per 100,000 persons.<xref ref-type="bibr" rid="article-17856.r25">[25]</xref>&#x000a0;According to epidemiologic data, RA is more prevalent in women compared to men, with a&#x000a0;lifetime risk of RA of 3.6% in women compared to 1.7% in men.<xref ref-type="bibr" rid="article-17856.r26">[26]</xref>&#x000a0;RA risk also increases with age, with a peak incidence between age 65 to 80 years of age.<xref ref-type="bibr" rid="article-17856.r27">[27]</xref><xref ref-type="bibr" rid="article-17856.r28">[28]</xref><xref ref-type="bibr" rid="article-17856.r27">[27]</xref>&#x000a0;A systematic review of population-based studies (including 60 studies) showed a worldwide period prevalence of RA of 0.51% (1955-2015).<xref ref-type="bibr" rid="article-17856.r29">[29]</xref>&#x000a0;</p>
        <p>The period prevalence of RA was more in urban areas (0.69%) than in rural areas (0.54%). The period prevalence of RA was higher in high-income countries (0.49%) compared to low-income countries (0.35.%).<xref ref-type="bibr" rid="article-17856.r30">[30]</xref> RA prevalence was higher in North America and Europe and lower in Asia and South America (See Table below).<xref ref-type="bibr" rid="article-17856.r29">[29]</xref>&#x000a0;Data from Africa is limited and varies significantly by country, with RA being more common in North Africa and lower in sub-Saharan Africa.<xref ref-type="bibr" rid="article-17856.r30">[30]</xref>&#x000a0;RA is much less prevalent in East Asia compared to the rest of Asia.<xref ref-type="bibr" rid="article-17856.r30">[30]</xref> There was an increase in the global period prevalence of 9.75% over time between 1980-2019 in a meta-analysis of 67 studies.<xref ref-type="bibr" rid="article-17856.r30">[30]</xref></p>
        <p>As outlined above, there is a genetic disposition towards RA, which was demonstrated to be about 40% in a large study from Sweden in 2013.<xref ref-type="bibr" rid="article-17856.r31">[31]</xref>&#x000a0;The study also reported a higher heritability for seropositive RA and early-onset RA. According to their report, the risk of RA with a first-degree relative positive for RA is three-fold higher than a second-degree relative with RA giving a two-fold higher risk.<xref ref-type="bibr" rid="article-17856.r31">[31]</xref>&#x000a0;Multiple different genetic predispositions to explain this finding have now been identified. The strongest genetic predisposition for RA is from the&#x000a0;HLA-DRB1 region (shared epitope).<xref ref-type="bibr" rid="article-17856.r8">[8]</xref></p>
        <p>Among modifiable risk factors, cigarette smoking has the strongest association with RA.<xref ref-type="bibr" rid="article-17856.r22">[22]</xref>&#x000a0;Diet and nutrition have been shown to play a significant role as environmental triggers for RA. The typical 'western' diet that is rich, high in caloric content, and low in fiber increases the risk of RA.<xref ref-type="bibr" rid="article-17856.r32">[32]</xref>&#x000a0;Consumption of long-chain omega-3 polyunsaturated fatty acids is associated with a reduced risk of RA.<xref ref-type="bibr" rid="article-17856.r32">[32]</xref>&#x000a0;&#x000a0;</p>
        <p>Obesity is another well-established risk factor for RA. There is a 30% increase in the risk of RA for patients with a body mass index (BMI) of greater than 30 kg/m^2 and a 15% increased risk for those with a BMI of 25 to 29.9 kg/m^2.<xref ref-type="bibr" rid="article-17856.r33">[33]</xref></p>
        <p>There is significant literature regarding the association of RA in patients with chronic mucosal or periodontal disease. However, no clear, consistent link has been identified in well-established studies. There is evidence that mucosal injury from occupational exposures and environmental pollutants can increase the risk of RA.<xref ref-type="bibr" rid="article-17856.r34">[34]</xref><xref ref-type="bibr" rid="article-17856.r35">[35]</xref><xref ref-type="bibr" rid="article-17856.r1">[1]</xref><xref ref-type="bibr" rid="article-17856.r35">[35]</xref></p>
        <p>&#x000a0;<bold>Prevalence of RA (period prevalence 1955-2015)</bold><xref ref-type="bibr" rid="article-17856.r30">[30]</xref></p>
        <p>&#x000a0;Continent/Number of Studies/RA Pooled Prevalence (95%CI)</p>
        <table-wrap id="article-17856.table2" position="float" orientation="portrait">
          <table style="height: 317px;" border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr>
                <td style="width: 365px;" rowspan="1" colspan="1">
<italic toggle="yes">North America</italic>
</td>
                <td style="width: 365px;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;10</td>
                <td style="width: 365px;" rowspan="1" colspan="1">0.70% (0.57-0.86)</td>
              </tr>
              <tr>
                <td style="width: 365px;" rowspan="1" colspan="1">Europe</td>
                <td style="width: 365px;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; 26</td>
                <td style="width: 365px;" rowspan="1" colspan="1">0.54% (0.50-0.59)</td>
              </tr>
              <tr>
                <td style="width: 365px;" rowspan="1" colspan="1">Africa</td>
                <td style="width: 365px;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;3</td>
                <td style="width: 365px;" rowspan="1" colspan="1">0.52% (0.00-1.74)</td>
              </tr>
              <tr>
                <td style="width: 365px;" rowspan="1" colspan="1">Asia</td>
                <td style="width: 365px;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; 26</td>
                <td style="width: 365px;" rowspan="1" colspan="1">0.30% (0.23-0.37)</td>
              </tr>
              <tr>
                <td style="width: 365px;" rowspan="1" colspan="1">South America</td>
                <td style="width: 365px;" rowspan="1" colspan="1">&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;2</td>
                <td style="width: 365px;" rowspan="1" colspan="1">0.30% (0.09-0.62)</td>
              </tr>
              <tr>
                <td style="width: 365px;" rowspan="1" colspan="1">
<bold>Global</bold>
</td>
                <td style="width: 365px;" rowspan="1" colspan="1">
<bold>&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;67</bold>
</td>
                <td style="width: 365px;" rowspan="1" colspan="1">
<bold>0.46% (0.39-0.54)</bold>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="article-17856.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>RA, in some patients, is triggered by some sort of environmental factor in a genetically predisposed host. The best example is tobacco use in a patient with the HLA-DRB1 "shared epitope" gene and the development of ACPA-positive RA.<xref ref-type="bibr" rid="article-17856.r1">[1]</xref>&#x000a0; RF and&#x000a0;ACPA antibodies are the best-known autoantibodies in RA, but several other autoantibodies are relatively specific for RA. The presence of antibodies in rheumatoid arthritis is referred to as seropositive RA. RF is an antibody of any isotype that binds to the Fc portion of IgG.</p>
        <p>RA patients often have antibodies to citrullinated proteins. These antibodies have been identified in patients with RA since 1964 (antiperinuclear factor)<xref ref-type="bibr" rid="article-17856.r36">[36]</xref> and were also described in 1979 (anti-keratin antibodies)<xref ref-type="bibr" rid="article-17856.r37">[37]</xref> by different assays. In the 1990s, these antibodies were determined to be the same antibodies with high specificity for RA.<xref ref-type="bibr" rid="article-17856.r38">[38]</xref>&#x000a0;The antibodies were found to have specificity for filaggrin, a citrullinated peptide.<xref ref-type="bibr" rid="article-17856.r39">[39]</xref><xref ref-type="bibr" rid="article-17856.r38">[38]</xref>&#x000a0;The epitope for these antibodies is citrullinated peptides. A cyclic citrullinated peptide (CCP) was synthesized, which could be used in an ELISA to test for these antibodies in patients in a clinical situation.<xref ref-type="bibr" rid="article-17856.r40">[40]</xref>&#x000a0; These antibodies are called anti-cyclic citrullinated peptide antibodies (ACPA). Citrulline is derived from the post-transcriptional modification of arginine by peptidyl arginine deiminase (PAD). This reaction occurs at sites of tissue damage and inflammation, such as the lungs in smokers. HLA-DRB1 shared epitope preferentially presents epitopes containing citrulline. ACPA can&#x000a0;be IgG,&#x000a0;IgM, or IgA isotypes. ACPA can bind citrullinated residues on self-proteins&#x000a0;like vimentin, fibronectin, fibrinogen, histones, and type 2 collagen.<xref ref-type="bibr" rid="article-17856.r23">[23]</xref>&#x000a0;</p>
        <p>Anti-carbamylated protein antibodies(anti-CarP antibodies) are also found in patients with RA. Carbamlyation is the conversion of lysine to homocitrulline in the presence of urea and cyanate. Myeloperoxidase converts thiocyanate to cyanate. The molecular structure of homocitrulline is similar to&#x000a0;citrulline; however, anti-CarP antibodies are distinct antibodies that have been associated with RA in both&#x000a0;ACPA-positive and ACPA-negative patients.<xref ref-type="bibr" rid="article-17856.r23">[23]</xref>&#x000a0;There are other autoantibodies that have been described in RA patients, including those directed against fibrinogen, enolase, and vimentin.<xref ref-type="bibr" rid="article-17856.r41">[41]</xref></p>
        <p>The immune response in RA starts at sites distant from the synovial joints, such as the lung, gums, and GI tract.<xref ref-type="bibr" rid="article-17856.r1">[1]</xref>&#x000a0; In these tissues, modified proteins are produced by biochemical reactions such as citrullination. The mechanism behind environment-triggered RA is thought to be due to the repeated activation of innate immunity. Using the lungs as an example, cigarette smoking induces peptidyl arginine deiminase (PAD) expression in alveolar macrophages, which leads to the conversion of arginine to citrulline in the airway.<xref ref-type="bibr" rid="article-17856.r42">[42]</xref>&#x000a0;This process creates a "neoantigen" that activates an immune response and leads to the formation of anti-citrullinated protein antibodies (ACPAs).<xref ref-type="bibr" rid="article-17856.r42">[42]</xref><xref ref-type="bibr" rid="article-17856.r23">[23]</xref></p>
        <p>Patients are genetically predisposed to develop an immune response to the modified proteins, anti-modified protein antibodies (AMPA). Citrullination is produced by the action of PAD on arginine. Isoforms PAD2 and PAD4 are most strongly implicated in RA. Anti-PAD4 antibodies are found in patients with RA, are highly specific for RA, and are associated with ACPA positivity.<xref ref-type="bibr" rid="article-17856.r43">[43]</xref>&#x000a0;in other mucosal areas, the inflammatory response in gingivitis is associated with the presence of&#x000a0;<italic toggle="yes">Porphyromonas gingivalis,</italic> which causes an inflammatory reaction. There is an influx of leukocytes that produce PAD4.&#x000a0;<italic toggle="yes">P gingivalis</italic> also produces a PAD-like enzyme. These enzymes can citrullinate resident proteins, which then can act as autoantigens.<xref ref-type="bibr" rid="article-17856.r44">[44]</xref>&#x000a0;Anti-acetylated protein antibodies have recently been associated with RA (in approximately 40% of RA patients), predominately in seropositive patients.<xref ref-type="bibr" rid="article-17856.r23">[23]</xref>&#x000a0;Acetylation is an enzymatic process converting lysine to acetyllysine, thought to be mediated by bacteria, which may provide a link to RA and microbiome dysbiosis. The exact mechanism at this time remains unclear.<xref ref-type="bibr" rid="article-17856.r23">[23]</xref>&#x000a0;So there are several types of modified proteins that can be the target of autoantibodies produced by citrullination, carbamylation, and acetylation.<xref ref-type="bibr" rid="article-17856.r45">[45]</xref><xref ref-type="bibr" rid="article-17856.r46">[46]</xref></p>
        <p>Autoantibodies appear before the onset of clinical arthritis.<xref ref-type="bibr" rid="article-17856.r47">[47]</xref><xref ref-type="bibr" rid="article-17856.r41">[41]</xref>&#x000a0;Autoimmunity starts at the molecular and cellular level long before the clinical phase of RA, often referred to as pre-symptomatic or pre-clinical RA. During this phase, certain immunologic and biochemical abnormalities have been found, but the patients are asymptomatic.<xref ref-type="bibr" rid="article-17856.r48">[48]</xref><xref ref-type="bibr" rid="article-17856.r49">[49]</xref><xref ref-type="bibr" rid="article-17856.r47">[47]</xref>&#x000a0;RF and ACPA&#x000a0;can be present in the serum up to 10 years before the onset of clinical symptoms. With&#x000a0;time the concentration of ACPA and serum cytokine levels increase.<xref ref-type="bibr" rid="article-17856.r50">[50]</xref><xref ref-type="bibr" rid="article-17856.r23">[23]</xref>&#x000a0;Many patients develop autoantibodies but do not develop the overt disease. Some patients will eventually transition from autoimmunity to immune-mediated inflammation primarily focused in the synovium.<xref ref-type="bibr" rid="article-17856.r1">[1]</xref>&#x000a0;These autoantibodies are produced by plasma cells in the synovium. The synovium in&#x000a0;RA is infiltrated by immune cells, which include innate immune cells (monocytes, dendritic cells, mast cells) and adaptive immune cells (T-helper 1, Th1); T-helper 17, Th17), B cells, and plasma cells). Synovial fibroblast-like synovial cells (FSC) are activated. Neutrophils are not present in the synovium but egress from the blood to the synovial fluid.<xref ref-type="bibr" rid="article-17856.r51">[51]</xref>&#x000a0;</p>
        <p>Cytokines and chemokines such as tumor necrosis factor (TNF), interleukin-6 (IL-6), and granulocyte-monocyte colony-stimulating factor (GM-CSF) activate endothelial cells and attract immune cells within the synovial compartment.<xref ref-type="bibr" rid="article-17856.r23">[23]</xref>&#x000a0;The FSC in the rheumatoid&#x000a0;synovium changes to an&#x000a0;invasive phenotype. FSC and inflammatory cells produce RANKL leads to osteoclast generation resulting in bone erosions, the hallmark feature of rheumatoid arthritis.<xref ref-type="bibr" rid="article-17856.r52">[52]</xref>&#x000a0;It is important to note that synovial biopsies in seropositive patients with arthralgia were essentially unremarkable.<xref ref-type="bibr" rid="article-17856.r53">[53]</xref>&#x000a0;It is theorized that a second environmental trigger is needed to cause clinically apparent disease. When this is established, a destructive inflammatory process begins. Fibroblast-like synoviocytes (FLS) migrate from joint to joint, leading to progressive joint damage.<xref ref-type="bibr" rid="article-17856.r52">[52]</xref></p>
        <p>All elements of the immune system are involved, including innate immunity and adaptive immunity, which includes the cellular (T cell) immune response and the humeral (B cell) immune response.<xref ref-type="bibr" rid="article-17856.r54">[54]</xref><xref ref-type="bibr" rid="article-17856.r46">[46]</xref>&#x000a0;The innate immune response includes macrophages which produce TNF, IL-6, IL-1, GM-CSF, IL-15, IL-18, IL-32, and chemokines which promote tissue inflammation.<xref ref-type="bibr" rid="article-17856.r54">[54]</xref>&#x000a0;Other elements of innate immunity include cells such as endothelial cells, which allow the egress of immune and inflammatory cells such as neutrophils which migrate to the synovial fluid and produce prostaglandins, proteases, and reactive oxygen intermediates, all of which are pro-inflammatory and cause destruction to the cartilage.<xref ref-type="bibr" rid="article-17856.r54">[54]</xref><xref ref-type="bibr" rid="article-17856.r51">[51]</xref>&#x000a0;</p>
        <p>Resident fibroblasts-like synoviocytes (FLS) are activated by proinflammatory cytokines, PGDF, and chemokines to proliferate with invasive characteristics and produce matrix metalloproteinases (MMP) and ADAMTS. Chondrocytes are activated by TNF, IL-1, and IL-17, producing matric enzymes resulting in cartilage damage. Resident mast cells produce vasoactive amines, leukotrienes, proteases, and TNF. Osteoclasts are activated by RANKL, which plays a vital role in producing bone erosions.<xref ref-type="bibr" rid="article-17856.r51">[51]</xref>&#x000a0;Another element of innate immunity is the complement system which is activated by RF and ACPA-containing immune complexes producing C3a and C5a, which are&#x000a0;pro-inflammatory, attracting and activating neutrophils and also activating macrophages and mast cells.<xref ref-type="bibr" rid="article-17856.r51">[51]</xref></p>
        <p>Adaptive immunity includes T cells and B cells which respond to antigenic stimuli. In RA, one of the main antigens triggering autoimmunity is modified proteins such as citrullinated proteins.<xref ref-type="bibr" rid="article-17856.r1">[1]</xref><xref ref-type="bibr" rid="article-17856.r54">[54]</xref><xref ref-type="bibr" rid="article-17856.r51">[51]</xref><xref ref-type="bibr" rid="article-17856.r55">[55]</xref><xref ref-type="bibr" rid="article-17856.r45">[45]</xref><xref ref-type="bibr" rid="article-17856.r46">[46]</xref><xref ref-type="bibr" rid="article-17856.r56">[56]</xref>&#x000a0;At mucosal sites, T cells are activated by these modified proteins, which trigger B cells to produce AMPA, including ACPA. In some patients, this immune response develops into an immune-mediated inflammation in the synovium.<xref ref-type="bibr" rid="article-17856.r54">[54]</xref><xref ref-type="bibr" rid="article-17856.r51">[51]</xref>&#x000a0;T cells and B cells take up residence in the synovium populating the subsynovial region. The mononuclear cell infiltrate appears histologically like a lymphoid organ. Dendritic cells serve as a bridge between innate and adaptive immunity by presenting antigens to antigen-specific T cells.<xref ref-type="bibr" rid="article-17856.r54">[54]</xref><xref ref-type="bibr" rid="article-17856.r51">[51]</xref>&#x000a0;</p>
        <p>T cells interact with B cells, activating antigen-specific B cells to differentiate into plasma cells that produce RF and ACPA. These autoantibodies bind to their antigens forming immune complexes that can further the inflammatory response by activating the complement system.<xref ref-type="bibr" rid="article-17856.r51">[51]</xref><xref ref-type="bibr" rid="article-17856.r57">[57]</xref>&#x000a0;Some activated T cells become type 1 helper T cells (Th1) and type 17 helper T cells (Th17). Th17 cells produce IL-17, a proinflammatory cytokine that attracts other T cells and neutrophils.<xref ref-type="bibr" rid="article-17856.r54">[54]</xref><xref ref-type="bibr" rid="article-17856.r51">[51]</xref></p>
        <p>Cytokines are produced in large amounts in the synovium and play an important role in propagating an intense inflammatory response resulting in bone erosions and cartilage loss.<xref ref-type="bibr" rid="article-17856.r51">[51]</xref><xref ref-type="bibr" rid="article-17856.r54">[54]</xref><xref ref-type="bibr" rid="article-17856.r58">[58]</xref>&#x000a0;Chronic inflammation also plays a role in associated comorbidities, such as the increased risk of cardiovascular disease. The following table outlines the most important cytokine involved in the pathogenesis of RA.</p>
        <p>
<bold>Cytokines and Chemokines (CXC) Involved in the Pathogenesis of RA</bold>
</p>
        <p>FLS = fibroblast-like synoviocytes; MCP-1 = macrophage chemoattractant protein-1; ILC3 = innate lymphoid cell group 3; MMP = matric metalloproteinase; NO = nitric oxide; PG = prostaglandins<xref ref-type="bibr" rid="article-17856.r51">[51]</xref></p>
        <table-wrap id="article-17856.table3" position="float" orientation="portrait">
          <table style="height: 410px; width: 1599px;" border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr style="height: 13px;">
                <td style="width: 356px; height: 13px;" rowspan="1" colspan="1">Cytokine</td>
                <td style="width: 356px; height: 13px;" rowspan="1" colspan="1">Source of cytokine</td>
                <td style="width: 173px; height: 13px;" rowspan="1" colspan="1">Cytokine receptor</td>
                <td style="width: 539px; height: 13px;" rowspan="1" colspan="1">Biologic effects of cytokine</td>
              </tr>
              <tr style="height: 48px;">
                <td style="width: 356px; height: 48px;" rowspan="1" colspan="1">TNF-alpha</td>
                <td style="width: 356px; height: 48px;" rowspan="1" colspan="1">Macrophages, FLS, Endothelial cells</td>
                <td style="width: 173px; height: 48px;" rowspan="1" colspan="1">TNFRSF1, TNFRSF2</td>
                <td style="width: 539px; height: 48px;" rowspan="1" colspan="1">
<p>FLS activation and proliferation, resulting in pannus, activation of chondrocytes, osteoclasts, and endothelial cells.</p>
</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 356px; height: 13px;" rowspan="1" colspan="1">IFN-gamma</td>
                <td style="width: 356px; height: 13px;" rowspan="1" colspan="1">T cells, NK cells, Macrophages, B cells, Dendritic cells</td>
                <td style="width: 173px; height: 13px;" rowspan="1" colspan="1">IFNGR1, IFNGR2</td>
                <td style="width: 539px; height: 13px;" rowspan="1" colspan="1">Activation of antigen-presenting cells by upregulating MHC Class II genes.</td>
              </tr>
              <tr style="height: 26px;">
                <td style="width: 356px; height: 26px;" rowspan="1" colspan="1">IL-1</td>
                <td style="width: 356px; height: 26px;" rowspan="1" colspan="1">Macrophages, FLS, Chondrocytes</td>
                <td style="width: 173px; height: 26px;" rowspan="1" colspan="1">IL-1R1, IL-1R2</td>
                <td style="width: 539px; height: 26px;" rowspan="1" colspan="1">Activates FLS, macrophages, neutrophils, T and B cells, osteoclasts, and chondrocytes, promoting TNF-alpha and IL-6 production, PGE2 production, and production of MMPs.</td>
              </tr>
              <tr style="height: 26px;">
                <td style="width: 356px; height: 26px;" rowspan="1" colspan="1">&#x000a0;IL-6</td>
                <td style="width: 356px; height: 26px;" rowspan="1" colspan="1">Macrophages, FLS, T cells, endothelial cells</td>
                <td style="width: 173px; height: 26px;" rowspan="1" colspan="1">Heterodimer of IL-6R-alpha and gp 130</td>
                <td style="width: 539px; height: 26px;" rowspan="1" colspan="1">&#x000a0;B cell activation and differentiation, Th17 activation and differentiation, osteoclast formation, and stimulates the liver to synthesize acute phase proteins.</td>
              </tr>
              <tr style="height: 26px;">
                <td style="width: 356px; height: 26px;" rowspan="1" colspan="1">&#x000a0;IL-15</td>
                <td style="width: 356px; height: 26px;" rowspan="1" colspan="1">&#x000a0;Macrophages, Dendritic cells, endothelial cells, FLS</td>
                <td style="width: 173px; height: 26px;" rowspan="1" colspan="1">&#x000a0;Heterotrimer of IL-15R-alpha, IL-15R-beta, and gamma-c</td>
                <td style="width: 539px; height: 26px;" rowspan="1" colspan="1">Chemotactic and activation factor for T cells induces the production of TNF-alpha, MMP, MCP-1, and IL-8.</td>
              </tr>
              <tr style="height: 39px;">
                <td style="width: 356px; height: 39px;" rowspan="1" colspan="1">IL-17</td>
                <td style="width: 356px; height: 39px;" rowspan="1" colspan="1">Th17 cells, ILC3</td>
                <td style="width: 173px; height: 39px;" rowspan="1" colspan="1">Hertodimer of IL-17RA and IL-17RB, IL-17C, or IL-17E</td>
                <td style="width: 539px; height: 39px;" rowspan="1" colspan="1">Activates and attracts T cells and neutrophils, activates FLS, macrophages, endothelial cells, osteoclasts, and chondrocytes, stimulates the production of TNF-alpha, IL1-beta, IL-6, IL-8, IL-23, chemokines, nitric oxide (NO), PG, GM-CSF, MMPs, promotes RANKL</td>
              </tr>
              <tr style="height: 26px;">
                <td style="width: 356px; height: 26px;" rowspan="1" colspan="1">IL-18</td>
                <td style="width: 356px; height: 26px;" rowspan="1" colspan="1">Macrophages, Dendritic cells, FLS</td>
                <td style="width: 173px; height: 26px;" rowspan="1" colspan="1">Heterodimer of IL-18R-alpha and IL-18R-beta</td>
                <td style="width: 539px; height: 26px;" rowspan="1" colspan="1">Stimulates macrophages, T cells, and NK cells to produce TNF-alpha, IL-1-beta, and GM-CSF, which activates neutrophils.</td>
              </tr>
              <tr style="height: 26px;">
                <td style="width: 356px; height: 26px;" rowspan="1" colspan="1">IL-23</td>
                <td style="width: 356px; height: 26px;" rowspan="1" colspan="1">Macrophages, Dendritic cells, B cells</td>
                <td style="width: 173px; height: 26px;" rowspan="1" colspan="1">Heterodimer of IL-23R and IL-23R and IL-12R-beta-1</td>
                <td style="width: 539px; height: 26px;" rowspan="1" colspan="1">Induces differentiation of Th17 cells and osteoclasts, production of IL-6, TNF-alpha, IL-1-beta, and chemokines.</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 356px; height: 13px;" rowspan="1" colspan="1">IL-8 (Chemokine CXCL8)</td>
                <td style="width: 356px; height: 13px;" rowspan="1" colspan="1">&#x000a0;Macrophages, FLS, endothelial cells</td>
                <td style="width: 173px; height: 13px;" rowspan="1" colspan="1">CXCR1, CXCR2</td>
                <td style="width: 539px; height: 13px;" rowspan="1" colspan="1">Chemotactic and activation factors for neutrophils, T cells, and NK cells.</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 356px; height: 13px;" rowspan="1" colspan="1">Other chemokines in the CXC and CC families</td>
                <td style="width: 356px; height: 13px;" rowspan="1" colspan="1">Neutrophils, Macrophages, FLS, T cells, etc.</td>
                <td style="width: 173px; height: 13px;" rowspan="1" colspan="1">Various CXC and CC receptors</td>
                <td style="width: 539px; height: 13px;" rowspan="1" colspan="1">Attracts and promotes activation of neutrophils, macrophages, T cells, FLS, etc.&#x000a0;</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="article-17856.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>One of the earliest histopathologic findings in RA is new synovial blood vessel growth; this leads to the transmigration of lymphocytes and polymorphonuclear leukocytes into the synovial fluid. Angiogenesis is required to support the highly catabolic synovium and is accomplished via proinflammatory cytokines such as tumor necrosis factor (TNF).<xref ref-type="bibr" rid="article-17856.r59">[59]</xref>&#x000a0;With angiogenesis, cytokines activate endothelial cells to produce adhesion molecules which in turn facilitate cell migration into the synovium. Despite angiogenesis, RA synovial fluid is a hypoxic environment, leading to increased production of cyclooxygenase (COX) 2-derived nociceptive eicosanoids and matrix metalloproteinases (MMPs).<xref ref-type="bibr" rid="article-17856.r60">[60]</xref>&#x000a0;This further stimulates an inflammatory response in the synovium. During the early phase of the disease, the influx of inflammatory cells into the synovial membrane leads to a proliferation of monocytes and thickening of the synovial membrane with small villous projections into the joint space.<xref ref-type="bibr" rid="article-17856.r59">[59]</xref>&#x000a0;</p>
        <p>The histopathology of rheumatoid synovium reviews intense FLS activation and proliferation and subsynovial accumulation of T cells, including Th1, Th17, and Treg cells. B cells also accumulate and differentiate into plasma cells. The appearance of synovial tissue can appear similar to secondary lymphoid tissues such as lymph nodes. Macrophages, dendritic cells, mast cells, and fibroblasts are also present in the subsynovial tissue. Rheumatoid synovial tissue becomes invasive, eroding into the bone and causing marginal erosions.<xref ref-type="bibr" rid="article-17856.r2">[2]</xref></p>
        <p>Rheumatoid nodules initially have a small vessel vasculitis phenomenon followed by a chronic inflammatory granulomatous phase. The development of rheumatoid nodules is frequent in rheumatoid arthritis, involving the dermis or subcutis in peri-articular areas. When multiple, this phenomenon can be related to methotrexate therapy and is called accelerated rheumatoid nodulosis.<xref ref-type="bibr" rid="article-17856.r61">[61]</xref>&#x000a0;The size is variable and can range from a few&#x000a0;millimeters to centimeters. It appears grossly as a whitish&#x000a0;fibrous lesion with yellowish&#x000a0;areas corresponding to collagenous necrobiosis. The histological appearance can be indistinguishable from granuloma annulare. There are areas of irregular geographic-like necrobiosis of the dermis and hypodermis&#x000a0;surrounded by histiocytes arranged in a well-developed&#x000a0;palisade, occasional lymphocytes, and neutrophils. Occasionally, giant cells and mast cells can be present. Fibrin and collagen are&#x000a0;present in the center of the necrobiotic areas. The surrounding dermis and hypodermis have a&#x000a0;perivascular infiltrate of&#x000a0;plasma cells.<xref ref-type="bibr" rid="article-17856.r61">[61]</xref>&#x000a0;Very occasionally, rheumatoid nodules may occur in the lungs.</p>
      </sec>
      <sec id="article-17856.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The most common and predominant symptoms include joint pain and swelling, usually starting insidiously over a period of weeks to months. Initial joint involvement is typically in the small joints of the hands and feet, followed by larger joints. One of the hallmarks is stiffness, particularly morning stiffness.<xref ref-type="bibr" rid="article-17856.r2">[2]</xref><xref ref-type="bibr" rid="article-17856.r62">[62]</xref>&#x000a0;Usually, the onset of symptoms is slow and insidious; however, in some cases, an episodic pattern of symptoms can be seen and is defined as palindromic rheumatism.<xref ref-type="bibr" rid="article-17856.r63">[63]</xref>&#x000a0;Not all patients with palindromic rheumatism develop RA, and they respond to hydroxychloroquine which supports the idea that palindromic rheumatism is a distinct phenotype of RA.<xref ref-type="bibr" rid="article-17856.r64">[64]</xref>&#x000a0;</p>
        <p>As discussed above, RA involves small peripheral joints, usually of the hands. The axial joints can be involved, but this is limited to the cervical spine as there are synovial joints in this part of the spine. The lumbar spine is not involved.<xref ref-type="bibr" rid="article-17856.r65">[65]</xref>&#x000a0;Although multiple small joint involvements are a frequent feature, some patients may present with monoarticular and extraarticular involvement (lungs).<xref ref-type="bibr" rid="article-17856.r4">[4]</xref>&#x000a0;RA is a chronic progressive disease, and without treatment with disease-modifying anti-rheumatic drugs (DMARDs), patients will develop joint damage, deformities, disability, and increased mortality.<xref ref-type="bibr" rid="article-17856.r4">[4]</xref></p>
        <p>On physical examination, the affected joint will be painful if pressure is applied to the joint or on movement with or without joint swelling. Synovial thickening with a "boggy" feel on palpation will be noted. Joint erythema and warmth are usually absent, and wrist involvement may present with typical signs and symptoms of carpal tunnel syndrome. With multiple joint involvements, reduced grip strength will be seen on physical testing. The classical physical findings of ulnar deviation, metacarpophalangeal joint subluxation, ulnar deviation, swan neck deformity, Boutonniere deformity, and the "bowstring" sign are seen in advanced chronic disease. Other findings in the later stages of RA include a reduced range of motion in the shoulders, elbows, and knees. In the feet, hallux valgus is common, as well as other toe deformities.<xref ref-type="bibr" rid="article-17856.r4">[4]</xref></p>
        <p>Rheumatoid nodules are the most common extraarticular manifestations of RA.<xref ref-type="bibr" rid="article-17856.r66">[66]</xref>&#x000a0;They are commonly found on&#x000a0;pressure points such as the olecranon but may also occur over the joints of the hands and feet, the patella, and the Achilles tendons.</p>
        <p>Interstitial lung disease (ILD) affects 5 to 16% of patients with RA and is associated RA specific autoantibodies and increased mortality.<xref ref-type="bibr" rid="article-17856.r67">[67]</xref><xref ref-type="bibr" rid="article-17856.r68">[68]</xref><xref ref-type="bibr" rid="article-17856.r69">[69]</xref>&#x000a0;Some patients may present with ILD before developing joint inflammation with positive RF and ACPA. RA-associated ILD is associated with ACPA, anti-carbamylated protein antibodies (anti-CarP), and anti-malondialdehyde-acetaldehyde antibodies (anti-MAA).<xref ref-type="bibr" rid="article-17856.r70">[70]</xref><xref ref-type="bibr" rid="article-17856.r71">[71]</xref><xref ref-type="bibr" rid="article-17856.r72">[72]</xref>&#x000a0;The&#x000a0;<italic toggle="yes">MUC5B</italic> promoter variant rs35705950 is associated with ILD in patients with RA. This gene encodes mucin 5B, and this variant is a gain of function. RA-ILD compared to unaffected controls, the odds ratio is 3.8 (95% CI 2.8-5.2), and RA-ILD compared to RA without ILD, the odds ratio is 3.1 (95% CI 1.8-5.4).<xref ref-type="bibr" rid="article-17856.r73">[73]</xref></p>
        <p>Ophthalmological manifestations include secondary Sjogren syndrome with dry eyes and also dry mouth.<xref ref-type="bibr" rid="article-17856.r74">[74]</xref>&#x000a0; Also, inflammatory eye diseases such as episcleritis and scleritis have become uncommon with new therapies for RA. Similarly, Felty syndrome, which is the combination of long-standing seropositive RA (including RF and ANA), leukopenia, and splenomegaly, is rarely seen today. These patients may have chronic non-healing ulcers and an increased risk of bacterial infection. Vasculitis involving both medium and small-sized blood vessels can also be seen as a presenting symptom of RA. However, the prevalence of vasculitis among patients with RA is low.<xref ref-type="bibr" rid="article-17856.r75">[75]</xref>&#x000a0;Patients with rheumatoid vasculitis may exhibit mononeuritis multiplex or asymmetric polyneuropathy.</p>
      </sec>
      <sec id="article-17856.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Laboratory testing often reveals anemia of chronic disease and thrombocytosis. Neutropenia may be present if Felty syndrome is present (rare). RF is present in 80-90% of patients with RA, with a sensitivity of 69% and a specificity of 85%. ACPA is present in 70-80% of patients, with a sensitivity of 67% and a specificity of 95%.<xref ref-type="bibr" rid="article-17856.r76">[76]</xref>&#x000a0;Patients with RA with RF, ACPA, or both&#x000a0;are designated as having seropositive RA. About 10% of RA patients are seronegative, meaning they do not have RF or ACPA. The presence of&#x000a0;rheumatoid factor is not diagnostic of rheumatoid arthritis. It may be present in other connective tissue diseases such as systemic lupus erythematosus, Sjogren syndrome, scleroderma, and granulomatosis with polyangiitis. RF may also be found in patients with chronic infections and healthy individuals, albeit in low titers; if both RF and ACPA are positive, the sensitivity and specificity of the diagnosis increase substantially. RF and ACPA are present for months to years before the onset of clinical arthritis.<xref ref-type="bibr" rid="article-17856.r47">[47]</xref>&#x000a0;</p>
        <p>Therefore, when a patient presents with inflammatory arthritis, serological studies should be positive. In patients who are asymptomatic or those that have arthralgias, a positive RF and especially CCP predicts the onset of clinical RA.<xref ref-type="bibr" rid="article-17856.r77">[77]</xref><xref ref-type="bibr" rid="article-17856.r78">[78]</xref><xref ref-type="bibr" rid="article-17856.r79">[79]</xref>&#x000a0;Healthy relatives of patients with RA who have a positive RF and even more so with a positive ACPA are at increased risk for developing RA.<xref ref-type="bibr" rid="article-17856.r80">[80]</xref><xref ref-type="bibr" rid="article-17856.r81">[81]</xref>&#x000a0;Acute phase reactants, such as&#x000a0;erythrocyte sedimentation rate (ESR) and levels of C-reactive protein (CRP), are usually elevated in patients with active disease and should be obtained and can be used to assess disease activity when following patients with RA.&#x000a0;</p>
        <p>Synovial fluid examination usually reveals a leukocyte count between 1500 to 25,000/cubic mm and is predominantly polymorphonuclear cells. Cell counts higher than 25000/cubic mm are rare and can be seen with very active disease; however, they warrant workup to rule out underlying infection. The synovial fluid in RA will also reveal&#x000a0;low C3 and C4 levels despite elevated serum levels.<xref ref-type="bibr" rid="article-17856.r82">[82]</xref></p>
        <p>With advanced disease, joint involvement on plain radiographs will reveal periarticular osteopenia, joint space narrowing, and bony erosions (marginal). Erosions of cartilage and bone are considered pathognomonic findings for RA, although not absolutely specific. However, these findings are consistent with advanced disease.<xref ref-type="bibr" rid="article-17856.r83">[83]</xref>&#x000a0;Magnetic resonance imaging (MRI) and ultrasonography are useful in early disease before radiographic evidence of bone erosion occurs.<xref ref-type="bibr" rid="article-17856.r84">[84]</xref>&#x000a0;A decreased signal from the bone marrow on T1-weighted images and gadolinium-enhanced images indicates bone marrow edema. MRI can also reveal synovial thickening, which has been shown to predict the future presence of bony erosions.<xref ref-type="bibr" rid="article-17856.r85">[85]</xref>&#x000a0;The clinical utility of MRI and its incorporation into the diagnostic criteria for RA remains to be determined.&#x000a0;</p>
        <p>Due to the varied clinical presentation and lack of universal pathognomonic testing for RA, diagnosing the disease can be challenging early in the course of the disease. Traditionally the presence of at least four of the following criteria for at least six weeks would classify the patient as having RA. These criteria were: morning stiffness, arthritis of three or more joints, arthritis of the hands, symmetric arthritis, elevated acute phase reactants, elevated rheumatoid factor, and radiologic evidence of RA. These criteria separated inflammatory from non-inflammatory arthritis but were not very specific for RA. It was also not sensitive to early-stage RA, which was a significant drawback.<xref ref-type="bibr" rid="article-17856.r86">[86]</xref>&#x000a0;With the development of serologic markers, the diagnostic criteria were redefined. The 2010 American College of Rheumatology and the European League Against Rheumatism (ACR/EULAR) diagnostic criteria for RA are outlined below. It includes four different domains, which are as follows:</p>
        <p>
<bold>2010 ACR/EULAR Classification Criteria for RA</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Number and size of involved joints<xref ref-type="bibr" rid="article-17856.r87">[87]</xref>
<list list-type="bullet"><list-item><p>2 to 10 large joints = 1 point (shoulders, elbows, hips, knees, and ankles)</p></list-item><list-item><p>1 to 3 small joints = 2 points (metacarpophalangeal joints, proximal interphalangeal joints, second through fifth metatarsophalangeal joints, thumb interphalangeal joints, and wrists)</p></list-item><list-item><p>4 to 10 small joints = 3 points</p></list-item><list-item><p>Greater than 10 joints (including at least 1 small joint) = 5 points</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Serological testing for rheumatoid factor or anti-citrullinated peptide/protein antibody<xref ref-type="bibr" rid="article-17856.r87">[87]</xref>
<list list-type="bullet"><list-item><p>Low positive = 2 points</p></list-item><list-item><p>High positive = 3 points</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Elevated acute phase reactant (erythrocyte sedimentation rate [ESR] or C-reactive protein [CRP]) = 1 point<xref ref-type="bibr" rid="article-17856.r87">[87]</xref></p>
          </list-item>
          <list-item>
            <p>Symptom duration of at least six weeks = 1 point<xref ref-type="bibr" rid="article-17856.r87">[87]</xref></p>
          </list-item>
        </list>
        <p>A total score greater than or equal to 6 classifies the patient as having RA. Note that these are classification and diagnostic criteria, so their primary purpose is being used in clinical studies of patients with RA, including clinical trials. It is important to note that joint involvement refers to any swollen or tender joint on examination. Imaging studies may also be used to determine the presence of synovitis/joint involvement. The 2010 ACR/EALAR criteria excluded distal interphalangeal joints, first carpometacarpal joints, and first metatarsophalangeal joints from this criteria. Also, these criteria may only be applied to those patients where the joint involvement is not better explained by other inflammatory diseases, such as systemic lupus erythematosus or psoriasis. Specific testing must be obtained to rule out these diseases. The new criteria were noted to better predict the probability of RA, have the same sensitivity as the previous criteria for the diagnosis of RA and have a higher specificity as well as a higher negative predictive value.<xref ref-type="bibr" rid="article-17856.r86">[86]</xref></p>
      </sec>
      <sec id="article-17856.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The goal of treatment in patients with RA is early diagnosis and early initiation of treatment to prevent irreversible damage to the joints. The International Task Force Guidelines published in 2014 make the following recommendations regarding the treatment of RA:<xref ref-type="bibr" rid="article-17856.r88">[88]</xref>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>The primary goal of treatment is to achieve long-term clinical remission and optimize quality of life with the absence of signs and symptoms associated with inflammatory disease activity.</p>
          </list-item>
          <list-item>
            <p>If clinical remission cannot be achieved, low disease activity is an acceptable alternative.</p>
          </list-item>
          <list-item>
            <p>Disease activity should be assessed every month in patients with moderate to severe disease activity.</p>
          </list-item>
          <list-item>
            <p>In patients with low disease activity or clinical remission, disease activity should be assessed every 3 to 6 months.</p>
          </list-item>
        </list>
        <p>Multiple clinical assessment tools have been developed to assist clinicians in determining the disease activity of patients with RA. An updated recommendation from the American College of Rheumatology (ACR) in 2019 recommended using the following assessment tools because they met the&#x000a0;minimum standard for evaluation per their recommendation.<xref ref-type="bibr" rid="article-17856.r89">[89]</xref><xref ref-type="bibr" rid="article-17856.r90">[90]</xref>&#x000a0;In clinical practice, the combination of the DAS28, CDAI, and RAPID3 is easy to use and includes patient input, provider input, and laboratory tests.</p>
        <list list-type="bullet">
          <list-item>
            <p>Clinical Disease Activity Index (CDAI)&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Disease Activity Score (DAS)</p>
          </list-item>
          <list-item>
            <p>Disease Activity Score 28 Joints (DAS28-ESR/CRP)</p>
          </list-item>
          <list-item>
            <p>Patient-Derived DAS28</p>
          </list-item>
          <list-item>
            <p>Hospital Universitario La Princesa Index (HUPI)</p>
          </list-item>
          <list-item>
            <p>Multi-Biomarker Disease Activity Score (MBDA score,&#x000a0;VECTRA DA)</p>
          </list-item>
          <list-item>
            <p>Rheumatoid Arthritis Disease Activity Index (RADAI)</p>
          </list-item>
          <list-item>
            <p>Rheumatoid Arthritis Disease Activity Index 5 (RADAI-5)</p>
          </list-item>
          <list-item>
            <p>Routine Assessment of Patient Index Data 3 (RAPID3)</p>
          </list-item>
          <list-item>
            <p>Routine Assessment of Patient Index Data 5 (RAPID5)</p>
          </list-item>
          <list-item>
            <p>Simplified Disease Activity Index (SDAI)</p>
          </list-item>
        </list>
        <p>Disease-modifying antirheumatic drugs (DMARDs) typically used in treating RA include methotrexate, hydroxychloroquine, sulfasalazine, and leflunomide. Anti-TNF-alpha inhibitors include etanercept, infliximab, adalimumab, golimumab, and certolizumab pegol. Other biologic DMARDs include interleukin (IL) 6 inhibitors such as tocilizumab and sarilumab, T-cell costimulation inhibitors such as abatacept (CTLA4-Ig), and the anti-CD20 B-cell depleting monoclonal antibody such as rituximab. Targeted synthetic DMARDs include Janus kinases (JAK) inhibitors such as&#x000a0;tofacitinib, baricitinib, and upadacitinib.<xref ref-type="bibr" rid="article-17856.r2">[2]</xref><xref ref-type="bibr" rid="article-17856.r4">[4]</xref></p>
        <p>DMARD therapy, including biologic agents and targeted synthetic agents (tofacitinib), should be temporarily held in patients with a serious active infection. They can be resumed after the infection has resolved and antimicrobial treatment has been completed.<xref ref-type="bibr" rid="article-17856.r91">[91]</xref> It is essential to remember that all patients starting treatment for RA should be screened for hepatitis B and C and tuberculosis. Methotrexate should be avoided in patients with liver disease.<xref ref-type="bibr" rid="article-17856.r91">[91]</xref>&#x000a0;Patients with latent tuberculosis should complete treatment for at least one month before initiating biologic and targeted synthetic agents. If patients cannot take or complete treatment for latent tuberculosis, conventional DMARD therapy should be used.<xref ref-type="bibr" rid="article-17856.r91">[91]</xref>&#x000a0;In patients with underlying skin cancer and lymphoproliferative disorders, biologic agents should be avoided except for rituximab in patients with lymphoproliferative disorders, as there is evidence of benefit from B-cell suppression in these cases.<xref ref-type="bibr" rid="article-17856.r91">[91]</xref>&#x000a0;The ACR also recommends that before starting therapy for RA, patients should receive vaccination for pneumococcus, hepatitis, influenza, human papillomavirus (HPV), herpes zoster virus (HZV), and COVID-19.</p>
        <p>
<bold>Non-steroidal Anti-inflammatory Drugs (NSAIDs)</bold>
</p>
        <p>NSAIDs do not have any disease-modifying effects but are commonly used to relieve symptoms related to joint inflammation and pain. There are about 20 such drugs (depending on what country you are in) that are all effective at full doses. There is some variation in side effects and toxicities. There is a class Black Box warning for cardiovascular disease, although there is variation in the cardiovascular effects among NSAIDs.<xref ref-type="bibr" rid="article-17856.r92">[92]</xref><xref ref-type="bibr" rid="article-17856.r93">[93]</xref>&#x000a0;NSAIDs also have the potential for gastrointestinal, renal, and hematologic toxicity. The choice of a specific NSAID depends on the patient, their comorbidities, and the provider's familiarity with the specific drug. Non-acetylated salicylates (salsalate) have an excellent safety profile with little GI, renal, or hematologic effects but are not commonly used. There are recommendations for using NSAIDs with regard to a patient's cardiovascular and gastrointestinal comorbidities.<xref ref-type="bibr" rid="article-17856.r94">[94]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Efficacy: indomethacin, piroxicam</p>
          </list-item>
          <list-item>
            <p>Convenience (1-2 doses per day): meloxicam, naproxen, celecoxib, nabumetone</p>
          </list-item>
          <list-item>
            <p>Overall safety: nabumetone<xref ref-type="bibr" rid="article-17856.r95">[95]</xref></p>
          </list-item>
          <list-item>
            <p>GI safety: celecoxib, nabumetone</p>
          </list-item>
          <list-item>
            <p>Renal safety: possible nabumetone</p>
          </list-item>
          <list-item>
            <p>Hematologic safety (no antiplatelet effect): celecoxib, meloxicam, nabumetone</p>
          </list-item>
        </list>
        <p>
<bold>Corticosteroids</bold>
</p>
        <p>Corticosteroids are commonly used in patients with RA. There are several situations in which corticosteroids should be considered. In a new patient with very active RA, corticosteroids can be used as bridge therapy while DMARD therapy is instituted. Some studies show that using corticosteroids early in RA patients improves outcomes and has disease-modifying effects, including radiographic progression.<xref ref-type="bibr" rid="article-17856.r96">[96]</xref><xref ref-type="bibr" rid="article-17856.r97">[97]</xref>&#x000a0;Another study did not show long-term benefits from corticosteroid bridge therapy.<xref ref-type="bibr" rid="article-17856.r98">[98]</xref>&#x000a0;Short courses of corticosteroids can be used for mild flares of RA. Intra-articular corticosteroids can be used for single-joint flares. About 50% of patients with RA require low-dose corticosteroids (prednisone 2.5&#x000a0;to 7.5 mg daily to maintain control of their disease. Long-term corticosteroids are associated with numerous toxicities, including weight gain, osteoporosis, and increased risk of infections.</p>
        <p>
<bold>Nonbiologic DMARDs</bold>
</p>
        <p>This category includes methotrexate, hydroxychloroquine (HCQ), azathioprine (AZA), sulfasalazine, leflunomide, and cyclosporine. Methotrexate is the initial drug of choice for patients with RA. The recommended treatment plan recommends an initial dose of 10-15 mg/week of methotrexate with an escalation of 5 mg/month and a target dose of 20-25 mg/week.<xref ref-type="bibr" rid="article-17856.r99">[99]</xref>&#x000a0;Subcutaneous administration can be tried in patients who do not respond adequately or are intolerant to oral administration.<xref ref-type="bibr" rid="article-17856.r100">[100]</xref>&#x000a0;In patients on methotrexate, 15 mg/week or higher, who still have some disease activity, splitting the dose (10 mg in the morning and 10 mg in the evening every week) increased the bioavailability of methotrexate.<xref ref-type="bibr" rid="article-17856.r101">[101]</xref>&#x000a0;Triple therapy, consisting of the combination of methotrexate, hydroxychloroquine, and sulfasalazine, has been shown to be an effective regimen for RA.<xref ref-type="bibr" rid="article-17856.r102">[102]</xref><xref ref-type="bibr" rid="article-17856.r103">[103]</xref>&#x000a0;However, triple therapy is not well tolerated, and a large percentage of patients do stay on this therapy.<xref ref-type="bibr" rid="article-17856.r104">[104]</xref><xref ref-type="bibr" rid="article-17856.r105">[105]</xref><xref ref-type="bibr" rid="article-17856.r106">[106]</xref></p>
        <p>
<bold>TNF inhibitors</bold>
</p>
        <p>The TNF inhibitors include etanercept, infliximab, adalimumab, certolizumab, and golimumab. The ACR does not recommend using TNF inhibitors until a nonbiologic DMARD has been tried.<xref ref-type="bibr" rid="article-17856.r91">[91]</xref>&#x000a0;However, studies have shown that adding TNF inhibitors in patients who have failed methotrexate therapy is better than adding another nonbiologic DMARD.<xref ref-type="bibr" rid="article-17856.r107">[107]</xref> The most concerning adverse effect of these agents is opportunistic infections and reactivation of latent tuberculosis. There is some concern about the generation of antibodies against these agents, which may decrease their efficacy over time; however, using methotrexate in combination with these agents has been shown to decrease this complication.<xref ref-type="bibr" rid="article-17856.r108">[108]</xref>&#x000a0;Acute infection, advanced heart failure, demyelinating disease, and recent malignancies are contraindications for using these agents.<xref ref-type="bibr" rid="article-17856.r91">[91]</xref>&#x000a0;</p>
        <p>
<bold>Rituximab</bold>
</p>
        <p>Rituximab is a biologic DMARD that can be added for treating RA if patients have uncontrolled RA and who did not respond to TNF inhibitors.<xref ref-type="bibr" rid="article-17856.r109">[109]</xref>&#x000a0;Rituximab is given as an intravenous infusion; it depletes CD20+ B-cells and decreases the immune response to vaccines in patients receiving rituximab. Responses to rituximab are better if the patients are seropositive and if the patients are also on methotrexate. As stated above, it is a preferred agent in patients with underlying lymphoproliferative disorders.&#x000a0;</p>
        <p>
<bold>Abatacept</bold>
</p>
        <p>Abatacept inhibits T-cell activation by binding to CD80 and CD86. It is administered as a monthly intravenous infusion or as a weekly subcutaneous injection. Patients with uncontrolled RA, who have shown an inadequate response to methotrexate and TNF inhibitor therapy, benefit from abatacept therapy with proven efficacy from 6 months to 5 years of therapy.<xref ref-type="bibr" rid="article-17856.r110">[110]</xref>&#x000a0;</p>
        <p>
<bold>Interleukin 6 Inhibitors</bold>
</p>
        <p>Tocilizumab, an IL-6 receptor inhibitor, is indicated for moderate-to-severe active RA in adults who have had an inadequate response to TNF inhibitor therapy. These patients develop clinically meaningful improvement with the use of tocilizumab.<xref ref-type="bibr" rid="article-17856.r111">[111]</xref>&#x000a0;Sarilumab is another agent in this category that has been shown to improve clinical outcomes in patients with uncontrolled RA despite TNF inhibitor therapy.<xref ref-type="bibr" rid="article-17856.r112">[112]</xref></p>
        <p>
<bold>Janus kinase (JAK) Inhibitors</bold>
</p>
        <p>JAK is a group of tyrosine kinases that participate in intracellular signal transduction for hematopoiesis and immune cell function. JAK inhibitors (such as tofacitinib) are oral agents that reduce the production of cytokines and are approved as second-line agents for the treatment of RA.<xref ref-type="bibr" rid="article-17856.r113">[113]</xref></p>
        <p>
<bold>ACR and EULAR Treatment Guidelines</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>According to the ACR treatment guidelines for early RA, patients who have not taken&#x000a0;disease-modifying antirheumatic drug (DMARD) therapy should start DMARD therapy regardless of the disease activity level.</p>
          </list-item>
          <list-item>
            <p>In patients with low disease activity and early disease, monotherapy with methotrexate is the preferred treatment.</p>
          </list-item>
          <list-item>
            <p>Leflunomide or sulfasalazine are the first-line treatment in patients with a contraindication to methotrexate or intolerance to it.</p>
          </list-item>
          <list-item>
            <p>If monotherapy with DMARD does not control disease activity (regardless of concomitant glucocorticoid use), therapy should be altered. Methotrexate can be continued or discontinued at this point. Additional therapy options after failed monotherapy with DMARD are recommended as either dual traditional/nonbiologic DMARD therapy, tumor necrosis factor (TNF) inhibitors, or non-tumor necrosis factor biologic agents.</p>
          </list-item>
          <list-item>
            <p>In patients with established RA, who are DMARD naive, methotrexate is the preferred agent for initial monotherapy, regardless of the disease activity level.</p>
          </list-item>
          <list-item>
            <p>If monotherapy with DMARD does not control disease activity in established RA (regardless of concomitant glucocorticoid use), dual DMARD therapy, a TNF inhibitor, a non-TNF biologic agent, or tofacitinib therapy can be added.</p>
          </list-item>
          <list-item>
            <p>If disease activity remains high on TNF inhibitor monotherapy, DMARD therapy should be added in addition to the TNF inhibitor.</p>
          </list-item>
          <list-item>
            <p>If disease activity remains high despite a TNF inhibitor switch to a non-TNF biologic agent with or without methotrexate</p>
          </list-item>
          <list-item>
            <p>If disease activity remains high despite a trial of anti-TNF and non-TNF agents, use another non-TNF biologic agent before considering tofacitinib.</p>
          </list-item>
          <list-item>
            <p>If still uncontrolled despite the above trials, use tofacitinib</p>
          </list-item>
          <list-item>
            <p>If disease activity remains high despite the above combination therapies, short-term low-dose glucocorticoid therapy should be added.</p>
          </list-item>
          <list-item>
            <p>TNF inhibitors should be avoided in patients with congestive heart failure.</p>
          </list-item>
          <list-item>
            <p>Patients with hepatitis C who have not been treated or are currently not on treatment for it should receive nonbiologic DMARD therapy rather than TNF inhibitors.<xref ref-type="bibr" rid="article-17856.r91">[91]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Safety Considerations with Biologic and Targeted Synthetic DMARDs</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Serious infections: All biologic and targeted synthetic DMARDs are associated with 2&#x000a0;to 3 times the number of infections. Hold all agents during an active infection, hold for surgical procedures, and avoid live vaccines. Opportunistic infections, including TB and fungal infections, all patients should be assessed for latent TB.</p>
          </list-item>
          <list-item>
            <p>Herpes zoster: JAK inhibitors</p>
          </list-item>
          <list-item>
            <p>Neutropenia: IL-6 inhibitors, JAK inhibitors, rituximab</p>
          </list-item>
          <list-item>
            <p>Elevated LFTs, elevated cholesterol: IL-6 inhibitors, JAK inhibitors</p>
          </list-item>
          <list-item>
            <p>Thrombosis: JAK inhibitors</p>
          </list-item>
          <list-item>
            <p>CHF: TNH inhibitors</p>
          </list-item>
          <list-item>
            <p>Cardiovascular events: JAK inhibitors (Black Box warning)</p>
          </list-item>
          <list-item>
            <p>Demyelinating diseases: TNF inhibitors</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17856.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Osteoarthritis</p>
          </list-item>
          <list-item>
            <p>Psoriatic arthritis</p>
          </list-item>
          <list-item>
            <p>Systemic lupus erythematosus</p>
          </list-item>
          <list-item>
            <p>Sjogren syndrome</p>
          </list-item>
          <list-item>
            <p>Polymyalgia rheumatic</p>
          </list-item>
          <list-item>
            <p>Chronic gouty arthritis</p>
          </list-item>
          <list-item>
            <p>Calcium pyrophosphate deposition disease</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17856.s11" sec-type="Staging">
        <title>Staging</title>
        <p>
<bold>Stages of RA as Defined by the ACR</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Stage 1: No destructive changes on X-rays</p>
          </list-item>
          <list-item>
            <p>Stage 2: Presence of X-ray evidence of periarticular osteoporosis, subchondral bone destruction but no joint deformity</p>
          </list-item>
          <list-item>
            <p>Stage 3: X-ray evidence of cartilage and bone destruction in addition to joint deformity and periarticular osteoporosis</p>
          </list-item>
          <list-item>
            <p>Stage 4: Presence of bony or fibrous ankylosis along with stage 3 features<xref ref-type="bibr" rid="article-17856.r91">[91]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17856.s12" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Rheumatoid arthritis has no cure and is a progressive disease associated with morbidity and increased mortality. All individuals&#x000a0;will experience multiple exacerbations and, without treatment, tend to have poor outcomes with disability and increased mortality.<xref ref-type="bibr" rid="article-17856.r114">[114]</xref><xref ref-type="bibr" rid="article-17856.r5">[5]</xref><xref ref-type="bibr" rid="article-17856.r114">[114]</xref>&#x000a0;Early treatment (within six months of symptom onset) has shown improved functional capacity and decreased disease activity as measured by swollen joint count and tender joint count. However, the mortality rate was similar in patients receiving early treatment and late treatment (after six months of symptoms), and both were significantly improved from no treatment.<xref ref-type="bibr" rid="article-17856.r114">[114]</xref> Approximately&#x000a0;40% of patients with RA will have a functional disability affecting their ability to work and complete activities of daily living within ten years of the diagnosis.<xref ref-type="bibr" rid="article-17856.r115">[115]</xref>&#x000a0;</p>
        <p>Patients with RA also develop other chronic medical conditions/complications which drastically affect their outcomes. The most notable of this correlation is the relationship between RA and atherosclerotic cardiovascular disease leading to accelerated coronary artery disease.<xref ref-type="bibr" rid="article-17856.r116">[116]</xref><xref ref-type="bibr" rid="article-17856.r117">[117]</xref>&#x000a0;RA increases the risk of cardiovascular disease, lung diseases, and malignancies, which in turn increases the risk of premature mortality in these patients.<xref ref-type="bibr" rid="article-17856.r118">[118]</xref></p>
      </sec>
      <sec id="article-17856.s13" sec-type="Complications">
        <title>Complications</title>
        <p>Complications of RA span multiple organ systems and are known to worsen clinical outcomes in patients with RA. It is imperative to monitor patients for the development of these complications and quickly alter treatment plans if applicable. Frequent recurrent serious opportunistic infections occur in patients with RA, which warrants withholding DMARD therapy until they are treated. The increased frequency of infections in patients with RA is thought to be due to underlying immune dysfunction from the disease itself and the use of DMARD therapy.<xref ref-type="bibr" rid="article-17856.r119">[119]</xref></p>
        <p>
<bold>Complications and Comorbidities Associated with Uncontrolled Systemic Inflammation</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Chronic joint inflammation results in radiographic damage, progressive deformity, and functional disability.</p>
          </list-item>
          <list-item>
            <p>Anemia of chronic disease and Felty syndrome are well-documented complications of seropositive RA.<xref ref-type="bibr" rid="article-17856.r74">[74]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>The secondary form of&#x000a0;Sj&#x000f6;gren syndrome is associated with RA and can have a prevalence of as high as 10% in patients with RA and pulmonary disease.<xref ref-type="bibr" rid="article-17856.r74">[74]</xref>&#x000a0;Other complications are uncommon to rare, including inflammatory eye disease and Felty's syndrome. Rheumatoid vasculitis is a rare phenomenon but can have severe complications if present. Clinical presentation ranges from focal digital involvement to severe systemic involvement resembling polyarteritis nodosa.<xref ref-type="bibr" rid="article-17856.r75">[75]</xref></p>
          </list-item>
          <list-item>
            <p>Pleuritis, bronchiolitis, and interstitial lung disease are also associated with RA. Although rare, RA treatment with methotrexate and anti-TNF agents can also lead to pulmonary injury. There is also an increased risk of pulmonary embolism in RA. Interstitial lung disease (ILD) affects 5 to 16% of RA patients and is associated with RA-specific autoantibodies and increased mortality.<xref ref-type="bibr" rid="article-17856.r67">[67]</xref><xref ref-type="bibr" rid="article-17856.r68">[68]</xref><xref ref-type="bibr" rid="article-17856.r69">[69]</xref>&#x000a0;Some patients may present with ILD before developing joint inflammation with positive RF and ACPA. RA-associated ILD is associated with ACPA, anti-carbamylated protein antibodies (anti-CarP), and anti-malondialdehyde-acetaldehyde antibodies (anti-MAA).<xref ref-type="bibr" rid="article-17856.r70">[70]</xref><xref ref-type="bibr" rid="article-17856.r71">[71]</xref><xref ref-type="bibr" rid="article-17856.r72">[72]</xref>&#x000a0;The&#x000a0;<italic toggle="yes">MUC5B</italic>&#x000a0;promoter variant rs35705950 is associated with ILD in patients with RA. This gene encodes mucin 5B, and this variant is a gain of function. RA-ILD compared to unaffected controls, the odds ratio is 3.8 (95% CI 2.8-5.2), and RA-ILD, compared to RA without ILD, the odds ratio is 3.1 (95% CI 1.8-5.4).<xref ref-type="bibr" rid="article-17856.r73">[73]</xref></p>
          </list-item>
          <list-item>
            <p>Coronary artery disease has a strong association with RA.<xref ref-type="bibr" rid="article-17856.r117">[117]</xref> RA is an independent risk factor for the development of coronary artery disease (CAD) and accelerates the development of CAD in these patients.<xref ref-type="bibr" rid="article-17856.r116">[116]</xref>&#x000a0;Accelerated atherosclerosis is the primary cause of morbidity and mortality in patients with RA leading to CAD and peripheral vascular disease.<xref ref-type="bibr" rid="article-17856.r120">[120]</xref>&#x000a0;There is increased insulin resistance and diabetes mellitus associated with RA, and is thought to be due to chronic inflammation. When treated with specific DMARDs such as hydroxychloroquine, methotrexate, and TNF antagonists, there was a marked improvement in glucose control in these patients.<xref ref-type="bibr" rid="article-17856.r121">[121]</xref>&#x000a0;The use of conventional and biologic DMARDs is associated with a reduced risk of cardiovascular events.<xref ref-type="bibr" rid="article-17856.r122">[122]</xref>&#x000a0;TNF inhibitors and abatacept appear to have the greatest effect on cardiovascular disease,&#x000a0;and the addition of methotrexate to biologic agents is associated with an even lower risk of cardiovascular events.<xref ref-type="bibr" rid="article-17856.r123">[123]</xref><xref ref-type="bibr" rid="article-17856.r124">[124]</xref></p>
          </list-item>
          <list-item>
            <p>Patients with RA also have a greater risk of developing lymphoma, with a higher incidence of non-Hodgkin lymphoma in these patients. The clinical course of RA in these patients is accelerated, and diffuse B-cell lymphoma is often the most common subtype.<xref ref-type="bibr" rid="article-17856.r125">[125]</xref>&#x000a0;Non-Hodgkin's lymphoma is more common in patients with RA, but this occurs mainly in patients with persistently active disease.<xref ref-type="bibr" rid="article-17856.r126">[126]</xref>&#x000a0;The use of biologic DMARDs does not appear to increase the risk of lymphoma.<xref ref-type="bibr" rid="article-17856.r127">[127]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Complications and Comorbidities Associated with RA Disease and Treatment</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Premature death</p>
          </list-item>
          <list-item>
            <p>Serious infections</p>
          </list-item>
          <list-item>
            <p>Osteopenia and osteoporosis are&#x000a0;complications of the disease itself and can also be associated with drug therapies (glucocorticoids). Compared to the general population, patients with RA have a 60% to 100% increased risk of fracture.<xref ref-type="bibr" rid="article-17856.r128">[128]</xref>&#x000a0;Patient factors that increase the risk of this complication in patients with RA are the same as those of osteoporosis, including postmenopausal state, low body mass index, and advanced age.</p>
          </list-item>
          <list-item>
            <p>There is an increased risk of venous thromboembolic disease in patients with RA, as stated above, even after adjusting for other risk factors for thromboembolic disease.<xref ref-type="bibr" rid="article-17856.r129">[129]</xref>&#x000a0;Multiple studies have reported a higher risk of thromboembolic disease in patients receiving TNF inhibitor&#x000a0;therapy and JAK inhibitors.<xref ref-type="bibr" rid="article-17856.r130">[130]</xref><xref ref-type="bibr" rid="article-17856.r131">[131]</xref> however, the consensus regarding this association is not well established. Some studies suggest that higher thromboembolic disease with the use of these agents is secondary to higher disease activity rather than an adverse effect of the agents.<xref ref-type="bibr" rid="article-17856.r131">[131]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Others</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Depression is a significant complication of RA. It is present in patients with long-term active disease and debilitating physical dysfunction. A 2013 meta-analysis reported a 17% to 39% prevalence of depression in patients with RA.<xref ref-type="bibr" rid="article-17856.r132">[132]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17856.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>RA has a strong genetic component and cannot be entirely avoided; however, modifiable risk factors such as cigarette smoking and consuming a balanced diet should be addressed. Patients at risk for RA should be counseled to eat a well-balanced diet, exercise regularly, and maintain healthy body weight.&#x000a0;</p>
      </sec>
      <sec id="article-17856.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Rheumatoid arthritis is a chronic disorder&#x000a0;with no cure. It&#x000a0;affects many other organs and is best managed with an interprofessional team to provide comprehensive care. The key is patient education&#x000a0;by nurses, pharmacists, rheumatologists, and primary care providers. The nurse should inform the patient about the signs and symptoms of different organ systems and when to seek medical care. The patient should enroll in an exercise program to recover joint function. An occupational therapy consult can help the patient manage daily living activities. The pharmacist should educate the patient on the types of drugs used to treat rheumatoid arthritis and their potential side effects while checking for interactions and reporting their findings to the team for therapy modification, if necessary.&#x000a0;</p>
        <p>At each clinic visit, clinicians and nurses should educate the&#x000a0;patient to stop smoking, maintain a healthy body weight, get the recommended vaccinations and eat a healthy diet.&#x000a0;The social worker should be involved in ensuring that the patient's home is liveable and the patient has ample support systems. The patient should be encouraged to join support groups. Due to progressive&#x000a0;disability, chronic pain, and poor quality of life, many patients become depressed and need a mental health nurse and counselor to cope with their disease. A comprehensive interprofessional team can provide a multi-faceted approach to treating RA and improving patient outcomes. [Level 5]</p>
        <p>RA has frequent relapses and remissions. While some&#x000a0;patients have mild disease, others may have a disease that severely affects their quality of life. Worse outcomes are usually seen in patients with a high titer of autoantibodies, HLA-DRB1 genotypes, age younger than 30 years at onset, multiple joint involvements, female gender, and extra-articular involvement on presentation. In addition, the drugs used to treat rheumatoid arthritis also have potent side effects, which&#x000a0;often are not well tolerated. As the disease progresses, many patients will develop adverse cardiac events leading to death. The overall mortality in patients with rheumatoid arthritis is three times higher than in the general population.<xref ref-type="bibr" rid="article-17856.r133">[133]</xref><xref ref-type="bibr" rid="article-17856.r134">[134]</xref>&#x000a0;A comprehensive interprofessional team approach to treating and monitoring patients with RA can help improve clinical outcomes for these patients. [Level 5]</p>
      </sec>
      <sec id="article-17856.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17856&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17856">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/arthritis/rheumatoid-arthritis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=17856">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17856/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17856">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-17856.s17">
        <fig id="article-17856.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Summary keynotes on Rheumatoid Arthritis Contributed by StatPearls</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="RA" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-17856.s18">
        <fig id="article-17856.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Ultrasound image of the thumb in a patient with a history of Rheumatoid Arthritis shows an abnormal amount of fluid within the flexor pollicus longus tendon sheath, consistent with an inflammatory tenosynovitis. Contributed by Mike Tall, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="TENOSYNOVITIS__34460057_US__EXTREMITY__COMPLETE__76881_24_0" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-17856.s19">
        <fig id="article-17856.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Granuloma annulare, H/E 20x. Palizading histiocytes and lymphocytes surround an area of necrobiotic collagen. Contributed by Fabiola Farci, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="granuloma__ann03" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-17856.s20">
        <title>References</title>
        <ref id="article-17856.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Klareskog</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>R&#x000f6;nnelid</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Saevarsdottir</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Padyukov</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Alfredsson</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>The importance of differences; On environment and its interactions with genes and immunity in the causation of rheumatoid arthritis.</article-title>
            <source>J Intern Med</source>
            <year>2020</year>
            <month>May</month>
            <volume>287</volume>
            <issue>5</issue>
            <fpage>514</fpage>
            <page-range>514-533</page-range>
            <pub-id pub-id-type="pmid">32176395</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smolen</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Aletaha</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>McInnes</surname>
                <given-names>IB</given-names>
              </name>
            </person-group>
            <article-title>Rheumatoid arthritis.</article-title>
            <source>Lancet</source>
            <year>2016</year>
            <month>Oct</month>
            <day>22</day>
            <volume>388</volume>
            <issue>10055</issue>
            <fpage>2023</fpage>
            <page-range>2023-2038</page-range>
            <pub-id pub-id-type="pmid">27156434</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bullock</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rizvi</surname>
                <given-names>SAA</given-names>
              </name>
              <name>
                <surname>Saleh</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Do</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Ansari</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Rheumatoid Arthritis: A Brief Overview of the Treatment.</article-title>
            <source>Med Princ Pract</source>
            <year>2018</year>
            <volume>27</volume>
            <issue>6</issue>
            <fpage>501</fpage>
            <page-range>501-507</page-range>
            <pub-id pub-id-type="pmid">30173215</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sparks</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Rheumatoid Arthritis.</article-title>
            <source>Ann Intern Med</source>
            <year>2019</year>
            <month>Jan</month>
            <day>01</day>
            <volume>170</volume>
            <issue>1</issue>
            <fpage>ITC1</fpage>
            <page-range>ITC1-ITC16</page-range>
            <pub-id pub-id-type="pmid">30596879</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pincus</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>O'Dell</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Kremer</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: a preventive strategy.</article-title>
            <source>Ann Intern Med</source>
            <year>1999</year>
            <month>Nov</month>
            <day>16</day>
            <volume>131</volume>
            <issue>10</issue>
            <fpage>768</fpage>
            <page-range>768-74</page-range>
            <pub-id pub-id-type="pmid">10577301</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Silman</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>MacGregor</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Thomson</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Holligan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Carthy</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Farhan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ollier</surname>
                <given-names>WE</given-names>
              </name>
            </person-group>
            <article-title>Twin concordance rates for rheumatoid arthritis: results from a nationwide study.</article-title>
            <source>Br J Rheumatol</source>
            <year>1993</year>
            <month>Oct</month>
            <volume>32</volume>
            <issue>10</issue>
            <fpage>903</fpage>
            <page-range>903-7</page-range>
            <pub-id pub-id-type="pmid">8402000</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>K&#x00142;odzi&#x00144;ski</surname>
                <given-names>&#x00141;</given-names>
              </name>
              <name>
                <surname>Wis&#x00142;owska</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Comorbidities in rheumatic arthritis.</article-title>
            <source>Reumatologia</source>
            <year>2018</year>
            <volume>56</volume>
            <issue>4</issue>
            <fpage>228</fpage>
            <page-range>228-233</page-range>
            <pub-id pub-id-type="pmid">30237627</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gregersen</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Silver</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Winchester</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis.</article-title>
            <source>Arthritis Rheum</source>
            <year>1987</year>
            <month>Nov</month>
            <volume>30</volume>
            <issue>11</issue>
            <fpage>1205</fpage>
            <page-range>1205-13</page-range>
            <pub-id pub-id-type="pmid">2446635</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weyand</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Hicok</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Conn</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Goronzy</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis.</article-title>
            <source>Ann Intern Med</source>
            <year>1992</year>
            <month>Nov</month>
            <day>15</day>
            <volume>117</volume>
            <issue>10</issue>
            <fpage>801</fpage>
            <page-range>801-6</page-range>
            <pub-id pub-id-type="pmid">1416553</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>du Teil Espina</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gabarrini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Harmsen</surname>
                <given-names>HJM</given-names>
              </name>
              <name>
                <surname>Westra</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>van Winkelhoff</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>van Dijl</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Talk to your gut: the oral-gut microbiome axis and its immunomodulatory role in the etiology of rheumatoid arthritis.</article-title>
            <source>FEMS Microbiol Rev</source>
            <year>2019</year>
            <month>Jan</month>
            <day>01</day>
            <volume>43</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-18</page-range>
            <pub-id pub-id-type="pmid">30219863</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Liao</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Long</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yin</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Lau</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>Q</given-names>
              </name>
            </person-group>
            <article-title>Pathogenic role of tissue-resident memory T cells in autoimmune diseases.</article-title>
            <source>Autoimmun Rev</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>17</volume>
            <issue>9</issue>
            <fpage>906</fpage>
            <page-range>906-911</page-range>
            <pub-id pub-id-type="pmid">30005862</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Okada</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Eyre</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kochi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Genetics of rheumatoid arthritis: 2018 status.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>78</volume>
            <issue>4</issue>
            <fpage>446</fpage>
            <page-range>446-453</page-range>
            <pub-id pub-id-type="pmid">30530827</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dedmon</surname>
                <given-names>LE</given-names>
              </name>
            </person-group>
            <article-title>The genetics of rheumatoid arthritis.</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>2020</year>
            <month>Oct</month>
            <day>01</day>
            <volume>59</volume>
            <issue>10</issue>
            <fpage>2661</fpage>
            <page-range>2661-2670</page-range>
            <pub-id pub-id-type="pmid">32638005</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Padyukov</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Genetics of rheumatoid arthritis.</article-title>
            <source>Semin Immunopathol</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>44</volume>
            <issue>1</issue>
            <fpage>47</fpage>
            <page-range>47-62</page-range>
            <pub-id pub-id-type="pmid">35088123</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ciccacci</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Conigliaro</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Perricone</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rufini</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Triggianese</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Politi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Novelli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Perricone</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Borgiani</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Polymorphisms in STAT-4, IL-10, PSORS1C1, PTPN2 and MIR146A genes are associated differently with prognostic factors in Italian patients affected by rheumatoid arthritis.</article-title>
            <source>Clin Exp Immunol</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>186</volume>
            <issue>2</issue>
            <fpage>157</fpage>
            <page-range>157-163</page-range>
            <pub-id pub-id-type="pmid">27342690</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stanford</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Maestre</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Bartok</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kiosses</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Boyle</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Arnett</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Mustelin</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Firestein</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Bottini</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Protein tyrosine phosphatase expression profile of rheumatoid arthritis fibroblast-like synoviocytes: a novel role of SH2 domain-containing phosphatase 2 as a modulator of invasion and survival.</article-title>
            <source>Arthritis Rheum</source>
            <year>2013</year>
            <month>May</month>
            <volume>65</volume>
            <issue>5</issue>
            <fpage>1171</fpage>
            <page-range>1171-80</page-range>
            <pub-id pub-id-type="pmid">23335101</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stolt</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bengtsson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nordmark</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lindblad</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lundberg</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Klareskog</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Alfredsson</surname>
                <given-names>L</given-names>
              </name>
              <collab>EIRA study group</collab>
            </person-group>
            <article-title>Quantification of the influence of cigarette smoking on rheumatoid arthritis: results from a population based case-control study, using incident cases.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2003</year>
            <month>Sep</month>
            <volume>62</volume>
            <issue>9</issue>
            <fpage>835</fpage>
            <page-range>835-41</page-range>
            <pub-id pub-id-type="pmid">12922955</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Padyukov</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Silva</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Stolt</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Alfredsson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Klareskog</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis.</article-title>
            <source>Arthritis Rheum</source>
            <year>2004</year>
            <month>Oct</month>
            <volume>50</volume>
            <issue>10</issue>
            <fpage>3085</fpage>
            <page-range>3085-92</page-range>
            <pub-id pub-id-type="pmid">15476204</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Linn-Rasker</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>van der Helm-van Mil</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>van Gaalen</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Kloppenburg</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>de Vries</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>le Cessie</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Breedveld</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Toes</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Huizinga</surname>
                <given-names>TW</given-names>
              </name>
            </person-group>
            <article-title>Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2006</year>
            <month>Mar</month>
            <volume>65</volume>
            <issue>3</issue>
            <fpage>366</fpage>
            <page-range>366-71</page-range>
            <pub-id pub-id-type="pmid">16014670</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Klareskog</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Stolt</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lundberg</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>K&#x000e4;llberg</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bengtsson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Grunewald</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>R&#x000f6;nnelid</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Ulfgren</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Rantap&#x000e4;&#x000e4;-Dahlqvist</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Eklund</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Padyukov</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Alfredsson</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination.</article-title>
            <source>Arthritis Rheum</source>
            <year>2006</year>
            <month>Jan</month>
            <volume>54</volume>
            <issue>1</issue>
            <fpage>38</fpage>
            <page-range>38-46</page-range>
            <pub-id pub-id-type="pmid">16385494</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lundstr&#x000f6;m</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>K&#x000e4;llberg</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Alfredsson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Klareskog</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Padyukov</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Gene-environment interaction between the DRB1 shared epitope and smoking in the risk of anti-citrullinated protein antibody-positive rheumatoid arthritis: all alleles are important.</article-title>
            <source>Arthritis Rheum</source>
            <year>2009</year>
            <month>Jun</month>
            <volume>60</volume>
            <issue>6</issue>
            <fpage>1597</fpage>
            <page-range>1597-603</page-range>
            <pub-id pub-id-type="pmid">19479873</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sugiyama</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nishimura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tamaki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tsuji</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nakazawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Morinobu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kumagai</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2010</year>
            <month>Jan</month>
            <volume>69</volume>
            <issue>1</issue>
            <fpage>70</fpage>
            <page-range>70-81</page-range>
            <pub-id pub-id-type="pmid">19174392</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Derksen</surname>
                <given-names>VFAM</given-names>
              </name>
              <name>
                <surname>Huizinga</surname>
                <given-names>TWJ</given-names>
              </name>
              <name>
                <surname>van der Woude</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>The role of autoantibodies in the pathophysiology of rheumatoid arthritis.</article-title>
            <source>Semin Immunopathol</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>39</volume>
            <issue>4</issue>
            <fpage>437</fpage>
            <page-range>437-446</page-range>
            <pub-id pub-id-type="pmid">28451788</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cross</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hoy</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Carmona</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wolfe</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Vos</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gabriel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lassere</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Johns</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Buchbinder</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Woolf</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>March</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>73</volume>
            <issue>7</issue>
            <fpage>1316</fpage>
            <page-range>1316-22</page-range>
            <pub-id pub-id-type="pmid">24550173</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Myasoedova</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Crowson</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Kremers</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Therneau</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Gabriel</surname>
                <given-names>SE</given-names>
              </name>
            </person-group>
            <article-title>Is the incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955-2007.</article-title>
            <source>Arthritis Rheum</source>
            <year>2010</year>
            <month>Jun</month>
            <volume>62</volume>
            <issue>6</issue>
            <fpage>1576</fpage>
            <page-range>1576-82</page-range>
            <pub-id pub-id-type="pmid">20191579</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crowson</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Matteson</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Myasoedova</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Michet</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Ernste</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Warrington</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Hunder</surname>
                <given-names>GG</given-names>
              </name>
              <name>
                <surname>Therneau</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Gabriel</surname>
                <given-names>SE</given-names>
              </name>
            </person-group>
            <article-title>The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases.</article-title>
            <source>Arthritis Rheum</source>
            <year>2011</year>
            <month>Mar</month>
            <volume>63</volume>
            <issue>3</issue>
            <fpage>633</fpage>
            <page-range>633-9</page-range>
            <pub-id pub-id-type="pmid">21360492</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eriksson</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Neovius</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ernestam</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lindblad</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Simard</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Askling</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Incidence of rheumatoid arthritis in Sweden: a nationwide population-based assessment of incidence, its determinants, and treatment penetration.</article-title>
            <source>Arthritis Care Res (Hoboken)</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>65</volume>
            <issue>6</issue>
            <fpage>870</fpage>
            <page-range>870-8</page-range>
            <pub-id pub-id-type="pmid">23281173</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Safiri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kolahi</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Hoy</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bettampadi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mansournia</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Almasi-Hashiani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ashrafi-Asgarabad</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Moradi-Lakeh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Qorbani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Woolf</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>March</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cross</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Global, regional and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the Global Burden of Disease study 2017.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>78</volume>
            <issue>11</issue>
            <fpage>1463</fpage>
            <page-range>1463-1471</page-range>
            <pub-id pub-id-type="pmid">31511227</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Almutairi</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Nossent</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Preen</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Keen</surname>
                <given-names>HI</given-names>
              </name>
              <name>
                <surname>Inderjeeth</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>The Prevalence of Rheumatoid Arthritis: A Systematic Review of Population-based Studies.</article-title>
            <source>J Rheumatol</source>
            <year>2021</year>
            <month>May</month>
            <volume>48</volume>
            <issue>5</issue>
            <fpage>669</fpage>
            <page-range>669-676</page-range>
            <pub-id pub-id-type="pmid">33060323</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Almutairi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nossent</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Preen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Keen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Inderjeeth</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review.</article-title>
            <source>Rheumatol Int</source>
            <year>2021</year>
            <month>May</month>
            <volume>41</volume>
            <issue>5</issue>
            <fpage>863</fpage>
            <page-range>863-877</page-range>
            <pub-id pub-id-type="pmid">33175207</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Frisell</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Holmqvist</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>K&#x000e4;llberg</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Klareskog</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Alfredsson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Askling</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Familial risks and heritability of rheumatoid arthritis: role of rheumatoid factor/anti-citrullinated protein antibody status, number and type of affected relatives, sex, and age.</article-title>
            <source>Arthritis Rheum</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>65</volume>
            <issue>11</issue>
            <fpage>2773</fpage>
            <page-range>2773-82</page-range>
            <pub-id pub-id-type="pmid">23897126</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Philippou</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Nikiphorou</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Are we really what we eat? Nutrition and its role in the onset of rheumatoid arthritis.</article-title>
            <source>Autoimmun Rev</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>17</volume>
            <issue>11</issue>
            <fpage>1074</fpage>
            <page-range>1074-1077</page-range>
            <pub-id pub-id-type="pmid">30213695</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Qin</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Zhong</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Body mass index and the risk of rheumatoid arthritis: a systematic review and dose-response meta-analysis.</article-title>
            <source>Arthritis Res Ther</source>
            <year>2015</year>
            <month>Mar</month>
            <day>29</day>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>86</fpage>
            <pub-id pub-id-type="pmid">25890172</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Sundquist</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sundquist</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Socioeconomic and occupational risk factors for rheumatoid arthritis: a nationwide study based on hospitalizations in Sweden.</article-title>
            <source>J Rheumatol</source>
            <year>2008</year>
            <month>Jun</month>
            <volume>35</volume>
            <issue>6</issue>
            <fpage>986</fpage>
            <page-range>986-91</page-range>
            <pub-id pub-id-type="pmid">18464310</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De Roos</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Koehoorn</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tamburic</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Brauer</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Proximity to traffic, ambient air pollution, and community noise in relation to incident rheumatoid arthritis.</article-title>
            <source>Environ Health Perspect</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>122</volume>
            <issue>10</issue>
            <fpage>1075</fpage>
            <page-range>1075-80</page-range>
            <pub-id pub-id-type="pmid">24905961</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>NIENHUIS</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>MANDEMA</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>A NEW SERUM FACTOR IN PATIENTS WITH RHEUMATOID ARTHRITIS; THE ANTIPERINUCLEAR FACTOR.</article-title>
            <source>Ann Rheum Dis</source>
            <year>1964</year>
            <month>Jul</month>
            <volume>23</volume>
            <issue>4</issue>
            <fpage>302</fpage>
            <page-range>302-5</page-range>
            <pub-id pub-id-type="pmid">14178016</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Young</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Mallya</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Hamblin</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Anti-keratin antibodies in rheumatoid arthritis.</article-title>
            <source>Br Med J</source>
            <year>1979</year>
            <month>Jul</month>
            <day>14</day>
            <volume>2</volume>
            <issue>6182</issue>
            <fpage>97</fpage>
            <page-range>97-9</page-range>
            <pub-id pub-id-type="pmid">111762</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sebbag</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Simon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vincent</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Masson-Bessi&#x000e8;re</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Girbal</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Durieux</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Serre</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies.</article-title>
            <source>J Clin Invest</source>
            <year>1995</year>
            <month>Jun</month>
            <volume>95</volume>
            <issue>6</issue>
            <fpage>2672</fpage>
            <page-range>2672-9</page-range>
            <pub-id pub-id-type="pmid">7539459</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hoet</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Boerbooms</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Arends</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ruiter</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>van Venrooij</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>Antiperinuclear factor, a marker autoantibody for rheumatoid arthritis: colocalisation of the perinuclear factor and profilaggrin.</article-title>
            <source>Ann Rheum Dis</source>
            <year>1991</year>
            <month>Sep</month>
            <volume>50</volume>
            <issue>9</issue>
            <fpage>611</fpage>
            <page-range>611-8</page-range>
            <pub-id pub-id-type="pmid">1718228</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schellekens</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Visser</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>de Jong</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>van den Hoogen</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>Hazes</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Breedveld</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>van Venrooij</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide.</article-title>
            <source>Arthritis Rheum</source>
            <year>2000</year>
            <month>Jan</month>
            <volume>43</volume>
            <issue>1</issue>
            <fpage>155</fpage>
            <page-range>155-63</page-range>
            <pub-id pub-id-type="pmid">10643712</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Delft</surname>
                <given-names>MAM</given-names>
              </name>
              <name>
                <surname>Huizinga</surname>
                <given-names>TWJ</given-names>
              </name>
            </person-group>
            <article-title>An overview of autoantibodies in rheumatoid arthritis.</article-title>
            <source>J Autoimmun</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>110</volume>
            <fpage>102392</fpage>
            <pub-id pub-id-type="pmid">31911013</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Makrygiannakis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hermansson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ulfgren</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Nicholas</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Zendman</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Eklund</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Grunewald</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Skold</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Klareskog</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Catrina</surname>
                <given-names>AI</given-names>
              </name>
            </person-group>
            <article-title>Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2008</year>
            <month>Oct</month>
            <volume>67</volume>
            <issue>10</issue>
            <fpage>1488</fpage>
            <page-range>1488-92</page-range>
            <pub-id pub-id-type="pmid">18413445</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Curran</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Naik</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Giles</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Darrah</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>PAD enzymes in rheumatoid arthritis: pathogenic effectors and autoimmune targets.</article-title>
            <source>Nat Rev Rheumatol</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>16</volume>
            <issue>6</issue>
            <fpage>301</fpage>
            <page-range>301-315</page-range>
            <pub-id pub-id-type="pmid">32341463</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>G&#x000f3;mez-Ba&#x000f1;uelos</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mukherjee</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Darrah</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Andrade</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Rheumatoid Arthritis-Associated Mechanisms of <italic>Porphyromonas gingivalis</italic> and <italic>Aggregatibacter actinomycetemcomitans</italic>.</article-title>
            <source>J Clin Med</source>
            <year>2019</year>
            <month>Aug</month>
            <day>26</day>
            <volume>8</volume>
            <issue>9</issue>
            <pub-id pub-id-type="pmid">31454946</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Volkov</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>van Schie</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>van der Woude</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Autoantibodies and B Cells: The ABC of rheumatoid arthritis pathophysiology.</article-title>
            <source>Immunol Rev</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>294</volume>
            <issue>1</issue>
            <fpage>148</fpage>
            <page-range>148-163</page-range>
            <pub-id pub-id-type="pmid">31845355</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McInnes</surname>
                <given-names>IB</given-names>
              </name>
              <name>
                <surname>Schett</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Pathogenetic insights from the treatment of rheumatoid arthritis.</article-title>
            <source>Lancet</source>
            <year>2017</year>
            <month>Jun</month>
            <day>10</day>
            <volume>389</volume>
            <issue>10086</issue>
            <fpage>2328</fpage>
            <page-range>2328-2337</page-range>
            <pub-id pub-id-type="pmid">28612747</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nielen</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>van Schaardenburg</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Reesink</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>van de Stadt</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>van der Horst-Bruinsma</surname>
                <given-names>IE</given-names>
              </name>
              <name>
                <surname>de Koning</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Habibuw</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Vandenbroucke</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Dijkmans</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors.</article-title>
            <source>Arthritis Rheum</source>
            <year>2004</year>
            <month>Feb</month>
            <volume>50</volume>
            <issue>2</issue>
            <fpage>380</fpage>
            <page-range>380-6</page-range>
            <pub-id pub-id-type="pmid">14872479</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Steenbergen</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Huizinga</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>van der Helm-van Mil</surname>
                <given-names>AH</given-names>
              </name>
            </person-group>
            <article-title>The preclinical phase of rheumatoid arthritis: what is acknowledged and what needs to be assessed?</article-title>
            <source>Arthritis Rheum</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>65</volume>
            <issue>9</issue>
            <fpage>2219</fpage>
            <page-range>2219-32</page-range>
            <pub-id pub-id-type="pmid">23686440</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mankia</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Emery</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Preclinical Rheumatoid Arthritis: Progress Toward Prevention.</article-title>
            <source>Arthritis Rheumatol</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>68</volume>
            <issue>4</issue>
            <fpage>779</fpage>
            <page-range>779-88</page-range>
            <pub-id pub-id-type="pmid">26814677</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wegner</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lundberg</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kinloch</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fisher</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Malmstr&#x000f6;m</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Feldmann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Venables</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis.</article-title>
            <source>Immunol Rev</source>
            <year>2010</year>
            <month>Jan</month>
            <volume>233</volume>
            <issue>1</issue>
            <fpage>34</fpage>
            <page-range>34-54</page-range>
            <pub-id pub-id-type="pmid">20192991</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nandakumar</surname>
                <given-names>KS</given-names>
              </name>
            </person-group>
            <article-title>Molecular and Cellular Pathways Contributing to Joint Damage in Rheumatoid Arthritis.</article-title>
            <source>Mediators Inflamm</source>
            <year>2020</year>
            <volume>2020</volume>
            <fpage>3830212</fpage>
            <pub-id pub-id-type="pmid">32256192</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>L&#x000f3;pez-Mej&#x000ed;as</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Carmona</surname>
                <given-names>FD</given-names>
              </name>
              <name>
                <surname>Genre</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Remuzgo-Mart&#x000ed;nez</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez-Juanatey</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Corrales</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vicente</surname>
                <given-names>EF</given-names>
              </name>
              <name>
                <surname>Pulito-Cueto</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Miranda-Filloy</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Ram&#x000ed;rez Huaranga</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Blanco</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Robustillo-Villarino</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez-Carrio</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Alperi-L&#x000f3;pez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Alegre-Sancho</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Mijares</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Lera-G&#x000f3;mez</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>P&#x000e9;rez-Pamp&#x000ed;n</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ortega-Castro</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>L&#x000f3;pez-Pedrera</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a Vivar</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>G&#x000f3;mez-Arango</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Raya</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Narvaez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Balsa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>L&#x000f3;pez-Longo</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Carreira</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez-&#x000c1;lvaro</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez-Rodr&#x000ed;guez</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fern&#x000e1;ndez-Guti&#x000e9;rrez</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ferraz-Amaro</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Gualillo</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Casta&#x000f1;eda</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;n</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Llorca</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez-Gay</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Identification of a 3'-Untranslated Genetic Variant of RARB Associated With Carotid Intima-Media Thickness in Rheumatoid Arthritis: A Genome-Wide Association Study.</article-title>
            <source>Arthritis Rheumatol</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>71</volume>
            <issue>3</issue>
            <fpage>351</fpage>
            <page-range>351-360</page-range>
            <pub-id pub-id-type="pmid">30251476</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Hair</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>van de Sande</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Ramwadhdoebe</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Hansson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Landew&#x000e9;</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>van der Leij</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Maas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Serre</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>van Schaardenburg</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Klareskog</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gerlag</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>van Baarsen</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Tak</surname>
                <given-names>PP</given-names>
              </name>
            </person-group>
            <article-title>Features of the synovium of individuals at risk of developing rheumatoid arthritis: implications for understanding preclinical rheumatoid arthritis.</article-title>
            <source>Arthritis Rheumatol</source>
            <year>2014</year>
            <month>Mar</month>
            <volume>66</volume>
            <issue>3</issue>
            <fpage>513</fpage>
            <page-range>513-22</page-range>
            <pub-id pub-id-type="pmid">24574210</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McInnes</surname>
                <given-names>IB</given-names>
              </name>
              <name>
                <surname>Schett</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>The pathogenesis of rheumatoid arthritis.</article-title>
            <source>N Engl J Med</source>
            <year>2011</year>
            <month>Dec</month>
            <day>08</day>
            <volume>365</volume>
            <issue>23</issue>
            <fpage>2205</fpage>
            <page-range>2205-19</page-range>
            <pub-id pub-id-type="pmid">22150039</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Brito Rocha</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Baldo</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Andrade</surname>
                <given-names>LEC</given-names>
              </name>
            </person-group>
            <article-title>Clinical and pathophysiologic relevance of autoantibodies in rheumatoid arthritis.</article-title>
            <source>Adv Rheumatol</source>
            <year>2019</year>
            <month>Jan</month>
            <day>17</day>
            <volume>59</volume>
            <issue>1</issue>
            <fpage>2</fpage>
            <pub-id pub-id-type="pmid">30657101</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weyand</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Goronzy</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>The immunology of rheumatoid arthritis.</article-title>
            <source>Nat Immunol</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>10</fpage>
            <page-range>10-18</page-range>
            <pub-id pub-id-type="pmid">33257900</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lin</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Anzaghe</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sch&#x000fc;lke</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis.</article-title>
            <source>Cells</source>
            <year>2020</year>
            <month>Apr</month>
            <day>03</day>
            <volume>9</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">32260219</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kondo</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kuroda</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kobayashi</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Cytokine Networks in the Pathogenesis of Rheumatoid Arthritis.</article-title>
            <source>Int J Mol Sci</source>
            <year>2021</year>
            <month>Oct</month>
            <day>10</day>
            <volume>22</volume>
            <issue>20</issue>
            <pub-id pub-id-type="pmid">34681582</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lally</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Filer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Nash</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Buckley</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Rainger</surname>
                <given-names>GE</given-names>
              </name>
            </person-group>
            <article-title>A novel mechanism of neutrophil recruitment in a coculture model of the rheumatoid synovium.</article-title>
            <source>Arthritis Rheum</source>
            <year>2005</year>
            <month>Nov</month>
            <volume>52</volume>
            <issue>11</issue>
            <fpage>3460</fpage>
            <page-range>3460-9</page-range>
            <pub-id pub-id-type="pmid">16255036</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Demasi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cleland</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Cook-Johnson</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Effects of hypoxia on the expression and activity of cyclooxygenase 2 in fibroblast-like synoviocytes: interactions with monocyte-derived soluble mediators.</article-title>
            <source>Arthritis Rheum</source>
            <year>2004</year>
            <month>Aug</month>
            <volume>50</volume>
            <issue>8</issue>
            <fpage>2441</fpage>
            <page-range>2441-9</page-range>
            <pub-id pub-id-type="pmid">15334456</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chua-Aguilera</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>M&#x000f6;ller</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Yawalkar</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Skin Manifestations of Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, and Spondyloarthritides.</article-title>
            <source>Clin Rev Allergy Immunol</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>53</volume>
            <issue>3</issue>
            <fpage>371</fpage>
            <page-range>371-393</page-range>
            <pub-id pub-id-type="pmid">28752373</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Weinblatt</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Rheumatoid arthritis.</article-title>
            <source>Lancet</source>
            <year>2001</year>
            <month>Sep</month>
            <day>15</day>
            <volume>358</volume>
            <issue>9285</issue>
            <fpage>903</fpage>
            <page-range>903-11</page-range>
            <pub-id pub-id-type="pmid">11567728</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Koskinen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hannonen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sokka</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Palindromic rheumatism: longterm outcomes of 60 patients diagnosed in 1967-84.</article-title>
            <source>J Rheumatol</source>
            <year>2009</year>
            <month>Sep</month>
            <volume>36</volume>
            <issue>9</issue>
            <fpage>1873</fpage>
            <page-range>1873-5</page-range>
            <pub-id pub-id-type="pmid">19648311</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gonzalez-Lopez</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gamez-Nava</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Jhangri</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Russell</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Suarez-Almazor</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Decreased progression to rheumatoid arthritis or other connective tissue diseases in patients with palindromic rheumatism treated with antimalarials.</article-title>
            <source>J Rheumatol</source>
            <year>2000</year>
            <month>Jan</month>
            <volume>27</volume>
            <issue>1</issue>
            <fpage>41</fpage>
            <page-range>41-6</page-range>
            <pub-id pub-id-type="pmid">10648016</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lehtinen</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Kaarela</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Belt</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Kautiainen</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Kauppi</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Lehto</surname>
                <given-names>MU</given-names>
              </name>
            </person-group>
            <article-title>Incidence of acromioclavicular joint involvement in rheumatoid arthritis: a 15 year endpoint study.</article-title>
            <source>J Rheumatol</source>
            <year>1999</year>
            <month>Jun</month>
            <volume>26</volume>
            <issue>6</issue>
            <fpage>1239</fpage>
            <page-range>1239-41</page-range>
            <pub-id pub-id-type="pmid">10381036</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sayah</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>English</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Rheumatoid arthritis: a review of the cutaneous manifestations.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2005</year>
            <month>Aug</month>
            <volume>53</volume>
            <issue>2</issue>
            <fpage>191</fpage>
            <page-range>191-209; quiz 210-2</page-range>
            <pub-id pub-id-type="pmid">16021111</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bongartz</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nannini</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Medina-Velasquez</surname>
                <given-names>YF</given-names>
              </name>
              <name>
                <surname>Achenbach</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Crowson</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Ryu</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Vassallo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gabriel</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Matteson</surname>
                <given-names>EL</given-names>
              </name>
            </person-group>
            <article-title>Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study.</article-title>
            <source>Arthritis Rheum</source>
            <year>2010</year>
            <month>Jun</month>
            <volume>62</volume>
            <issue>6</issue>
            <fpage>1583</fpage>
            <page-range>1583-91</page-range>
            <pub-id pub-id-type="pmid">20155830</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sparks</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Vine</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Doyle</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>Prevalence, incidence and cause-specific mortality of rheumatoid arthritis-associated interstitial lung disease among older rheumatoid arthritis patients.</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>2021</year>
            <month>Aug</month>
            <day>02</day>
            <volume>60</volume>
            <issue>8</issue>
            <fpage>3689</fpage>
            <page-range>3689-3698</page-range>
            <pub-id pub-id-type="pmid">33462611</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Samhouri</surname>
                <given-names>BF</given-names>
              </name>
              <name>
                <surname>Vassallo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Achenbach</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Kronzer</surname>
                <given-names>VL</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Myasoedova</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Crowson</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>Incidence, Risk Factors, and Mortality of Clinical and Subclinical Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Population-Based Cohort.</article-title>
            <source>Arthritis Care Res (Hoboken)</source>
            <year>2022</year>
            <month>Dec</month>
            <volume>74</volume>
            <issue>12</issue>
            <fpage>2042</fpage>
            <page-range>2042-2049</page-range>
            <pub-id pub-id-type="pmid">34995017</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Correia</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Briones</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ostrowski</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Elevated anti-cyclic citrullinated peptide antibody titer is associated with increased risk for interstitial lung disease.</article-title>
            <source>Clin Rheumatol</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>38</volume>
            <issue>4</issue>
            <fpage>1201</fpage>
            <page-range>1201-1206</page-range>
            <pub-id pub-id-type="pmid">30645754</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Castellanos-Moreira</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rodriguez-Garcia</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Cabrera-Villalba</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gomara</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Salvador</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ruiz-Esquide</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ramirez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Inciarte-Mundo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Morla</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Garcia-Moreno</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cuervo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>G&#x000f3;mez-Puerta</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Ca&#x000f1;ete</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Haro</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Sanmarti</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Anti-carbamylated protein antibody isotype pattern differs between palindromic rheumatism and rheumatoid arthritis.</article-title>
            <source>Ther Adv Musculoskelet Dis</source>
            <year>2020</year>
            <volume>12</volume>
            <fpage>1759720X20978139</fpage>
            <pub-id pub-id-type="pmid">33354232</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>England</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Duryee</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Roul</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mahajan</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Poole</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Ascherman</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Caplan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Demoruelle</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Deane</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Klassen</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Thiele</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Mikuls</surname>
                <given-names>TR</given-names>
              </name>
            </person-group>
            <article-title>Malondialdehyde-Acetaldehyde Adducts and Antibody Responses in Rheumatoid Arthritis-Associated Interstitial Lung Disease.</article-title>
            <source>Arthritis Rheumatol</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>71</volume>
            <issue>9</issue>
            <fpage>1483</fpage>
            <page-range>1483-1493</page-range>
            <pub-id pub-id-type="pmid">30933423</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Juge</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Ebstein</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Furukawa</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Dobrinskikh</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gazal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kannengiesser</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ottaviani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Oka</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tohma</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tsuchiya</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rojas-Serrano</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez-P&#x000e9;rez</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Mej&#x000ed;a</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Buend&#x000ed;a-Rold&#x000e1;n</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Falf&#x000e1;n-Valencia</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ambrocio-Ortiz</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Manali</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Papiris</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Karageorgas</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Boumpas</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Antoniou</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>van Moorsel</surname>
                <given-names>CHM</given-names>
              </name>
              <name>
                <surname>van der Vis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>de Man</surname>
                <given-names>YA</given-names>
              </name>
              <name>
                <surname>Grutters</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Borie</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wemeau-Stervinou</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wallaert</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Flipo</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Nunes</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Valeyre</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Saidenberg-Kermanac'h</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Boissier</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Marchand-Adam</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Frazier</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Richette</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Allanore</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sibilia</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dromer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Richez</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schaeverbeke</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Liot&#x000e9;</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Thabut</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nathan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Amselem</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Soubrier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cottin</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Cl&#x000e9;ment</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Deane</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Walts</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Fingerlin</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ryu</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Matteson</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Niewold</surname>
                <given-names>TB</given-names>
              </name>
              <name>
                <surname>Assayag</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gross</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wolters</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Schwarz</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Holers</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Solomon</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Doyle</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rosas</surname>
                <given-names>IO</given-names>
              </name>
              <name>
                <surname>Blauwendraat</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nalls</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Debray</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Boileau</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Crestani</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Dieud&#x000e9;</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease.</article-title>
            <source>N Engl J Med</source>
            <year>2018</year>
            <month>Dec</month>
            <day>06</day>
            <volume>379</volume>
            <issue>23</issue>
            <fpage>2209</fpage>
            <page-range>2209-2219</page-range>
            <pub-id pub-id-type="pmid">30345907</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Conforti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Di Cola</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Pavlych</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ruscitti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Berardicurti</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Ursini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Giacomelli</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cipriani</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Beyond the joints, the extra-articular manifestations in rheumatoid arthritis.</article-title>
            <source>Autoimmun Rev</source>
            <year>2021</year>
            <month>Feb</month>
            <volume>20</volume>
            <issue>2</issue>
            <fpage>102735</fpage>
            <pub-id pub-id-type="pmid">33346115</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r75">
          <label>75</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abdulqader</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Al-Ani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Parperis</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Rheumatoid vasculitis: early presentation of rheumatoid arthritis.</article-title>
            <source>BMJ Case Rep</source>
            <year>2016</year>
            <month>Nov</month>
            <day>08</day>
            <volume>2016</volume>
            <pub-id pub-id-type="pmid">27873751</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r76">
          <label>76</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nishimura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sugiyama</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kogata</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tsuji</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nakazawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kawano</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Saigo</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Morinobu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Koshiba</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kuntz</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Kamae</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kumagai</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis.</article-title>
            <source>Ann Intern Med</source>
            <year>2007</year>
            <month>Jun</month>
            <day>05</day>
            <volume>146</volume>
            <issue>11</issue>
            <fpage>797</fpage>
            <page-range>797-808</page-range>
            <pub-id pub-id-type="pmid">17548411</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r77">
          <label>77</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rantap&#x000e4;&#x000e4;-Dahlqvist</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>de Jong</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Berglin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hallmans</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wadell</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Stenlund</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sundin</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>van Venrooij</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis.</article-title>
            <source>Arthritis Rheum</source>
            <year>2003</year>
            <month>Oct</month>
            <volume>48</volume>
            <issue>10</issue>
            <fpage>2741</fpage>
            <page-range>2741-9</page-range>
            <pub-id pub-id-type="pmid">14558078</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r78">
          <label>78</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Gaalen</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Linn-Rasker</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>van Venrooij</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>de Jong</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Breedveld</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Verweij</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Toes</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Huizinga</surname>
                <given-names>TW</given-names>
              </name>
            </person-group>
            <article-title>Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study.</article-title>
            <source>Arthritis Rheum</source>
            <year>2004</year>
            <month>Mar</month>
            <volume>50</volume>
            <issue>3</issue>
            <fpage>709</fpage>
            <page-range>709-15</page-range>
            <pub-id pub-id-type="pmid">15022309</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r79">
          <label>79</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Avouac</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gossec</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Dougados</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2006</year>
            <month>Jul</month>
            <volume>65</volume>
            <issue>7</issue>
            <fpage>845</fpage>
            <page-range>845-51</page-range>
            <pub-id pub-id-type="pmid">16606649</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r80">
          <label>80</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ramos-Remus</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Castillo-Ortiz</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Aguilar-Lozano</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Padilla-Ibarra</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sandoval-Castro</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vargas-Serafin</surname>
                <given-names>CO</given-names>
              </name>
              <name>
                <surname>de la Mora-Molina</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ramos-Gomez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sanchez-Ortiz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Avila-Armengol</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Aceves-Avila</surname>
                <given-names>FJ</given-names>
              </name>
            </person-group>
            <article-title>Autoantibodies in prediction of the development of rheumatoid arthritis among healthy relatives of patients with the disease.</article-title>
            <source>Arthritis Rheumatol</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>67</volume>
            <issue>11</issue>
            <fpage>2837</fpage>
            <page-range>2837-44</page-range>
            <pub-id pub-id-type="pmid">26245885</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r81">
          <label>81</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bemis</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Demoruelle</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Seifert</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Polinski</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Weisman</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Buckner</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Gregersen</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Mikuls</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>ODell</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Keating</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Deane</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Holers</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Norris</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Factors associated with progression to inflammatory arthritis in first-degree relatives of individuals with RA following autoantibody positive screening in a non-clinical setting.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2021</year>
            <month>Feb</month>
            <volume>80</volume>
            <issue>2</issue>
            <fpage>154</fpage>
            <page-range>154-161</page-range>
            <pub-id pub-id-type="pmid">32928740</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r82">
          <label>82</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kortekangas</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Aro</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Tuominen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Toivanen</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Synovial fluid leukocytosis in bacterial arthritis vs. reactive arthritis and rheumatoid arthritis in the adult knee.</article-title>
            <source>Scand J Rheumatol</source>
            <year>1992</year>
            <volume>21</volume>
            <issue>6</issue>
            <fpage>283</fpage>
            <page-range>283-8</page-range>
            <pub-id pub-id-type="pmid">1475638</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r83">
          <label>83</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fuchs</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Callahan</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Nance</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Pincus</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease.</article-title>
            <source>J Rheumatol</source>
            <year>1989</year>
            <month>May</month>
            <volume>16</volume>
            <issue>5</issue>
            <fpage>585</fpage>
            <page-range>585-91</page-range>
            <pub-id pub-id-type="pmid">2754663</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r84">
          <label>84</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McQueen</surname>
                <given-names>FM</given-names>
              </name>
            </person-group>
            <article-title>The use of MRI in early RA.</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>2008</year>
            <month>Nov</month>
            <volume>47</volume>
            <issue>11</issue>
            <fpage>1597</fpage>
            <page-range>1597-9</page-range>
            <pub-id pub-id-type="pmid">18701537</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r85">
          <label>85</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McQueen</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Crabbe</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Yeoman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>McLean</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals progression of erosions despite clinical improvement.</article-title>
            <source>Ann Rheum Dis</source>
            <year>1999</year>
            <month>Mar</month>
            <volume>58</volume>
            <issue>3</issue>
            <fpage>156</fpage>
            <page-range>156-63</page-range>
            <pub-id pub-id-type="pmid">10364913</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r86">
          <label>86</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cornec</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Varache</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Morvan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Devauchelle-Pensec</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Berthelot</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Le Henaff-Bourhis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hoang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chal&#x000e8;s</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Jousse-Joulin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Saraux</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Comparison of ACR 1987 and ACR/EULAR 2010 criteria for predicting a 10-year diagnosis of rheumatoid arthritis.</article-title>
            <source>Joint Bone Spine</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>79</volume>
            <issue>6</issue>
            <fpage>581</fpage>
            <page-range>581-5</page-range>
            <pub-id pub-id-type="pmid">22405855</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r87">
          <label>87</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aletaha</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Neogi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Silman</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Funovits</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Felson</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Bingham</surname>
                <given-names>CO</given-names>
              </name>
              <name>
                <surname>Birnbaum</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Burmester</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Bykerk</surname>
                <given-names>VP</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Combe</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Costenbader</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Dougados</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Emery</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ferraccioli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hazes</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Hobbs</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Huizinga</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Kavanaugh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kay</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kvien</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Laing</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mease</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>M&#x000e9;nard</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Moreland</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Naden</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Pincus</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Smolen</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Stanislawska-Biernat</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Symmons</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tak</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Upchurch</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Vencovsk&#x000fd;</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wolfe</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hawker</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.</article-title>
            <source>Arthritis Rheum</source>
            <year>2010</year>
            <month>Sep</month>
            <volume>62</volume>
            <issue>9</issue>
            <fpage>2569</fpage>
            <page-range>2569-81</page-range>
            <pub-id pub-id-type="pmid">20872595</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r88">
          <label>88</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smolen</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Breedveld</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Burmester</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Bykerk</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Dougados</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Emery</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kvien</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Navarro-Comp&#x000e1;n</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Oliver</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schoels</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Scholte-Voshaar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stamm</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Stoffer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Takeuchi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Aletaha</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Andreu</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Aringer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bergman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Betteridge</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bijlsma</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Burkhardt</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Cardiel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Combe</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Durez</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fonseca</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Gibofsky</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gomez-Reino</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Graninger</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Hannonen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Haraoui</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kouloumas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Landewe</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Martin-Mola</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Nash</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ostergaard</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>&#x000d6;st&#x000f6;r</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Richards</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sokka-Isler</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Thorne</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tzioufas</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>van Vollenhoven</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>de Wit</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>van der Heijde</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>75</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-15</page-range>
            <pub-id pub-id-type="pmid">25969430</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r89">
          <label>89</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anderson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Caplan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Yazdany</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Robbins</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Neogi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Michaud</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Saag</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>O'Dell</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Kazi</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice.</article-title>
            <source>Arthritis Care Res (Hoboken)</source>
            <year>2012</year>
            <month>May</month>
            <volume>64</volume>
            <issue>5</issue>
            <fpage>640</fpage>
            <page-range>640-7</page-range>
            <pub-id pub-id-type="pmid">22473918</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r90">
          <label>90</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>England</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Tiong</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Bergman</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Curtis</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Kazi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mikuls</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>O'Dell</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Ranganath</surname>
                <given-names>VK</given-names>
              </name>
              <name>
                <surname>Limanni</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Suter</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Michaud</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>2019 Update of the American College of Rheumatology Recommended Rheumatoid Arthritis Disease Activity Measures.</article-title>
            <source>Arthritis Care Res (Hoboken)</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>71</volume>
            <issue>12</issue>
            <fpage>1540</fpage>
            <page-range>1540-1555</page-range>
            <pub-id pub-id-type="pmid">31709779</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r91">
          <label>91</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Saag</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Bridges</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Akl</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Bannuru</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Vaysbrot</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>McNaughton</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Osani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shmerling</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Curtis</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Furst</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Parks</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kavanaugh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>O'Dell</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Leong</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Matteson</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Schousboe</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Drevlow</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ginsberg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Grober</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>St Clair</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>Tindall</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>McAlindon</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.</article-title>
            <source>Arthritis Rheumatol</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>68</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-26</page-range>
            <pub-id pub-id-type="pmid">26545940</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r92">
          <label>92</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Solomon</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Husni</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Wolski</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Wisniewski</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Borer</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Graham</surname>
                <given-names>DY</given-names>
              </name>
              <name>
                <surname>Libby</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lincoff</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>L&#x000fc;scher</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>Menon</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Yeomans</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Bao</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Berger</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Nissen</surname>
                <given-names>SE</given-names>
              </name>
              <collab>PRECISION Trial Investigators</collab>
            </person-group>
            <article-title>Differences in Safety of Nonsteroidal Antiinflammatory Drugs in Patients With Osteoarthritis and Patients With Rheumatoid Arthritis: A Randomized Clinical Trial.</article-title>
            <source>Arthritis Rheumatol</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>70</volume>
            <issue>4</issue>
            <fpage>537</fpage>
            <page-range>537-546</page-range>
            <pub-id pub-id-type="pmid">29266879</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r93">
          <label>93</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Solomon</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Husni</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Libby</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Yeomans</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Lincoff</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>L&#x003cb;scher</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>Menon</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Brennan</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Wisniewski</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Nissen</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Borer</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>The Risk of Major NSAID Toxicity with Celecoxib, Ibuprofen, or Naproxen: A Secondary Analysis of the PRECISION Trial.</article-title>
            <source>Am J Med</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>130</volume>
            <issue>12</issue>
            <fpage>1415</fpage>
            <page-range>1415-1422.e4</page-range>
            <pub-id pub-id-type="pmid">28756267</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r94">
          <label>94</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burmester</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lanas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Biasucci</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hermann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lohmander</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Olivieri</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Scarpignato</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Smolen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hawkey</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bajkowski</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Berenbaum</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Breedveld</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dieleman</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dougados</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>MacDonald</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mola</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Mets</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Van den Noortgate</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Stoevelaar</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2011</year>
            <month>May</month>
            <volume>70</volume>
            <issue>5</issue>
            <fpage>818</fpage>
            <page-range>818-22</page-range>
            <pub-id pub-id-type="pmid">20833736</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r95">
          <label>95</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ashworth</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Peloso</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Muhajarine</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Stang</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>A population based historical cohort study of the mortality associated with nabumetone, Arthrotec, diclofenac, and naproxen.</article-title>
            <source>J Rheumatol</source>
            <year>2004</year>
            <month>May</month>
            <volume>31</volume>
            <issue>5</issue>
            <fpage>951</fpage>
            <page-range>951-6</page-range>
            <pub-id pub-id-type="pmid">15124256</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r96">
          <label>96</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Everdingen</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Siewertsz Van Reesema</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Bijlsma</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial.</article-title>
            <source>Ann Intern Med</source>
            <year>2002</year>
            <month>Jan</month>
            <day>01</day>
            <volume>136</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-12</page-range>
            <pub-id pub-id-type="pmid">11777359</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r97">
          <label>97</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bakker</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Welsing</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Verstappen</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Tekstra</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ton</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Geurts</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>van der Werf</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>van Albada-Kuipers</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Jahangier-de Veen</surname>
                <given-names>ZN</given-names>
              </name>
              <name>
                <surname>van der Veen</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Verhoef</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Lafeber</surname>
                <given-names>FP</given-names>
              </name>
              <name>
                <surname>Bijlsma</surname>
                <given-names>JW</given-names>
              </name>
              <collab>Utrecht Rheumatoid Arthritis Cohort Study Group</collab>
            </person-group>
            <article-title>Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial.</article-title>
            <source>Ann Intern Med</source>
            <year>2012</year>
            <month>Mar</month>
            <day>06</day>
            <volume>156</volume>
            <issue>5</issue>
            <fpage>329</fpage>
            <page-range>329-39</page-range>
            <pub-id pub-id-type="pmid">22393128</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r98">
          <label>98</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krause</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mai</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Klaassen-Mielke</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Timmesfeld</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Trampisch</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Rudolf</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Baraliakos</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Schmitz</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fendler</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Klink</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Boeddeker</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Saracbasi-Zender</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Christoph</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Igelmann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Menne</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Schmid</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rau</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wassenberg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sonuc</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ose</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schade-Brittinger</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Trampisch</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Braun</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The Efficacy of Short-Term Bridging Strategies With High- and Low-Dose Prednisolone on Radiographic and Clinical Outcomes in Active Early Rheumatoid Arthritis: A Double-Blind, Randomized, Placebo-Controlled Trial.</article-title>
            <source>Arthritis Rheumatol</source>
            <year>2022</year>
            <month>Oct</month>
            <volume>74</volume>
            <issue>10</issue>
            <fpage>1628</fpage>
            <page-range>1628-1637</page-range>
            <pub-id pub-id-type="pmid">35643951</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r99">
          <label>99</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Visser</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>van der Heijde</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2009</year>
            <month>Jul</month>
            <volume>68</volume>
            <issue>7</issue>
            <fpage>1094</fpage>
            <page-range>1094-9</page-range>
            <pub-id pub-id-type="pmid">19033290</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r100">
          <label>100</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Braun</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>K&#x000e4;stner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Flaxenberg</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>W&#x000e4;hrisch</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hanke</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Demary</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>von Hin&#x000fc;ber</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Rockwitz</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Heitz</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Pichlmeier</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Guimbal-Schmolck</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Brandt</surname>
                <given-names>A</given-names>
              </name>
              <collab>MC-MTX.6/RH Study Group</collab>
            </person-group>
            <article-title>Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial.</article-title>
            <source>Arthritis Rheum</source>
            <year>2008</year>
            <month>Jan</month>
            <volume>58</volume>
            <issue>1</issue>
            <fpage>73</fpage>
            <page-range>73-81</page-range>
            <pub-id pub-id-type="pmid">18163521</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r101">
          <label>101</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hoekstra</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Haagsma</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Neef</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Proost</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Knuif</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>van de Laar</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Splitting high-dose oral methotrexate improves bioavailability: a pharmacokinetic study in patients with rheumatoid arthritis.</article-title>
            <source>J Rheumatol</source>
            <year>2006</year>
            <month>Mar</month>
            <volume>33</volume>
            <issue>3</issue>
            <fpage>481</fpage>
            <page-range>481-5</page-range>
            <pub-id pub-id-type="pmid">16463431</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r102">
          <label>102</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Dell</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Leff</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Paulsen</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Haire</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mallek</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Eckhoff</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Fernandez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Blakely</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wees</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stoner</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hadley</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Felt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Palmer</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Waytz</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Churchill</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Klassen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial.</article-title>
            <source>Arthritis Rheum</source>
            <year>2002</year>
            <month>May</month>
            <volume>46</volume>
            <issue>5</issue>
            <fpage>1164</fpage>
            <page-range>1164-70</page-range>
            <pub-id pub-id-type="pmid">12115219</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r103">
          <label>103</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Dell</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Mikuls</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Ahluwalia</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Brophy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Warren</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Lew</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Cannella</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Kunkel</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Phibbs</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Anis</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Leatherman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Keystone</surname>
                <given-names>E</given-names>
              </name>
              <collab>CSP 551 RACAT Investigators</collab>
            </person-group>
            <article-title>Therapies for active rheumatoid arthritis after methotrexate failure.</article-title>
            <source>N Engl J Med</source>
            <year>2013</year>
            <month>Jul</month>
            <day>25</day>
            <volume>369</volume>
            <issue>4</issue>
            <fpage>307</fpage>
            <page-range>307-18</page-range>
            <pub-id pub-id-type="pmid">23755969</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r104">
          <label>104</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sauer</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Teng</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Leng</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Curtis</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Mikuls</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Harrison</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Cannon</surname>
                <given-names>GW</given-names>
              </name>
            </person-group>
            <article-title>Persistence With Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in US Veterans With Rheumatoid Arthritis.</article-title>
            <source>Arthritis Care Res (Hoboken)</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>69</volume>
            <issue>3</issue>
            <fpage>313</fpage>
            <page-range>313-322</page-range>
            <pub-id pub-id-type="pmid">27273801</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r105">
          <label>105</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Erhardt</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Cannon</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Teng</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Mikuls</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Curtis</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Sauer</surname>
                <given-names>BC</given-names>
              </name>
            </person-group>
            <article-title>Low Persistence Rates in Patients With Rheumatoid Arthritis Treated With Triple Therapy and Adverse Drug Events Associated With Sulfasalazine.</article-title>
            <source>Arthritis Care Res (Hoboken)</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>71</volume>
            <issue>10</issue>
            <fpage>1326</fpage>
            <page-range>1326-1335</page-range>
            <pub-id pub-id-type="pmid">30221485</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r106">
          <label>106</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Curtis</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Palmer</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Reed</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Greenberg</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pappas</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Harrold</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Kremer</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis.</article-title>
            <source>Arthritis Care Res (Hoboken)</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>73</volume>
            <issue>8</issue>
            <fpage>1114</fpage>
            <page-range>1114-1124</page-range>
            <pub-id pub-id-type="pmid">32374918</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r107">
          <label>107</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karlsson</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Neovius</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nilsson</surname>
                <given-names>J&#x000c5;</given-names>
              </name>
              <name>
                <surname>Petersson</surname>
                <given-names>IF</given-names>
              </name>
              <name>
                <surname>Bratt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>van Vollenhoven</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Ernestam</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Geborek</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2013</year>
            <month>Dec</month>
            <volume>72</volume>
            <issue>12</issue>
            <fpage>1927</fpage>
            <page-range>1927-33</page-range>
            <pub-id pub-id-type="pmid">23196701</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r108">
          <label>108</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garc&#x000ea;s</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Demengeot</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Benito-Garcia</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2013</year>
            <month>Dec</month>
            <volume>72</volume>
            <issue>12</issue>
            <fpage>1947</fpage>
            <page-range>1947-55</page-range>
            <pub-id pub-id-type="pmid">23223420</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r109">
          <label>109</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Porter</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>van Melckebeke</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dale</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Messow</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>McConnachie</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Munro</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>McLaren</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>McRorie</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Packham</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Buckley</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Harvie</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Choy</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pitzalis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>McInnes</surname>
                <given-names>IB</given-names>
              </name>
            </person-group>
            <article-title>Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial.</article-title>
            <source>Lancet</source>
            <year>2016</year>
            <month>Jul</month>
            <day>16</day>
            <volume>388</volume>
            <issue>10041</issue>
            <fpage>239</fpage>
            <page-range>239-47</page-range>
            <pub-id pub-id-type="pmid">27197690</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r110">
          <label>110</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Genovese</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Pacheco-Tena</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Covarrubias</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Leon</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mysler</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Keiserman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Valente</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Nash</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Simon-Campos</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Box</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Legerton</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Nasonov</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Durez</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Elegbe</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Banerjee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Alten</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Longterm Safety and Efficacy of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: 5-year Results from a Phase IIIb Trial.</article-title>
            <source>J Rheumatol</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>45</volume>
            <issue>8</issue>
            <fpage>1085</fpage>
            <page-range>1085-1092</page-range>
            <pub-id pub-id-type="pmid">29657147</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r111">
          <label>111</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smolen</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Schoels</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Nishimoto</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Breedveld</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Burmester</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Dougados</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Emery</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ferraccioli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gabay</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gibofsky</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gomez-Reino</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kvien</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Murakami</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Betteridge</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bingham</surname>
                <given-names>CO</given-names>
              </name>
              <name>
                <surname>Bykerk</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Choy</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Combe</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Cutolo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Graninger</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Lanas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Martin-Mola</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Montecucco</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ostergaard</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pavelka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rubbert-Roth</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sattar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Scholte-Voshaar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Trauner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Valentini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Winthrop</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>de Wit</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>van der Heijde</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2013</year>
            <month>Apr</month>
            <volume>72</volume>
            <issue>4</issue>
            <fpage>482</fpage>
            <page-range>482-92</page-range>
            <pub-id pub-id-type="pmid">23172750</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r112">
          <label>112</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fleischmann</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>van Adelsberg</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Castelar-Pinheiro</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Brzezicki</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hrycaj</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Graham</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>van Hoogstraten</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bauer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Burmester</surname>
                <given-names>GR</given-names>
              </name>
            </person-group>
            <article-title>Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors.</article-title>
            <source>Arthritis Rheumatol</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>69</volume>
            <issue>2</issue>
            <fpage>277</fpage>
            <page-range>277-290</page-range>
            <pub-id pub-id-type="pmid">27860410</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r113">
          <label>113</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wallenstein</surname>
                <given-names>GV</given-names>
              </name>
              <name>
                <surname>Kanik</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Wilkinson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cutolo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fleischmann</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Genovese</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Gomez Reino</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gruben</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kremer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Krishnaswami</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Pascual-Ramos</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Strand</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Zwillich</surname>
                <given-names>SH</given-names>
              </name>
            </person-group>
            <article-title>Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised controlled trials.</article-title>
            <source>Clin Exp Rheumatol</source>
            <year>2016</year>
            <season>May-Jun</season>
            <volume>34</volume>
            <issue>3</issue>
            <fpage>430</fpage>
            <page-range>430-42</page-range>
            <pub-id pub-id-type="pmid">27156561</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r114">
          <label>114</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gwinnutt</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Symmons</surname>
                <given-names>DPM</given-names>
              </name>
              <name>
                <surname>MacGregor</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Chipping</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Marshall</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lunt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Verstappen</surname>
                <given-names>SMM</given-names>
              </name>
            </person-group>
            <article-title>Twenty-Year Outcome and Association Between Early Treatment and Mortality and Disability in an Inception Cohort of Patients With Rheumatoid Arthritis: Results From the Norfolk Arthritis Register.</article-title>
            <source>Arthritis Rheumatol</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>69</volume>
            <issue>8</issue>
            <fpage>1566</fpage>
            <page-range>1566-1575</page-range>
            <pub-id pub-id-type="pmid">28425173</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r115">
          <label>115</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paul</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Kandy</surname>
                <given-names>HI</given-names>
              </name>
              <name>
                <surname>Krishnan</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Pre-rheumatoid arthritis and its prevention.</article-title>
            <source>Eur J Rheumatol</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>4</volume>
            <issue>2</issue>
            <fpage>161</fpage>
            <page-range>161-165</page-range>
            <pub-id pub-id-type="pmid">28638695</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r116">
          <label>116</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Holmqvist</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mantel</surname>
                <given-names>&#x000c4;</given-names>
              </name>
              <name>
                <surname>W&#x000e5;llberg-Jonsson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jernberg</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Askling</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Findings on Coronary Angiographies in Patients With Rheumatoid Arthritis and Ischemic Heart Disease: Are They Different From Patients Without Rheumatoid Arthritis?</article-title>
            <source>Arthritis Care Res (Hoboken)</source>
            <year>2021</year>
            <month>May</month>
            <volume>73</volume>
            <issue>5</issue>
            <fpage>658</fpage>
            <page-range>658-665</page-range>
            <pub-id pub-id-type="pmid">33285616</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r117">
          <label>117</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Solomon</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Goodson</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Katz</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Weinblatt</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Avorn</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Setoguchi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Canning</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schneeweiss</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Patterns of cardiovascular risk in rheumatoid arthritis.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2006</year>
            <month>Dec</month>
            <volume>65</volume>
            <issue>12</issue>
            <fpage>1608</fpage>
            <page-range>1608-12</page-range>
            <pub-id pub-id-type="pmid">16793844</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r118">
          <label>118</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martin-Trujillo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>van Rietschoten</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Timmer</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Huizinga</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Tak</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Marsal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ibrahim</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Dijkmans</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>van der Pouw Kraan</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Verweij</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>Loss of imprinting of IGF2 characterises high IGF2 mRNA-expressing type of fibroblast-like synoviocytes in rheumatoid arthritis.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2010</year>
            <month>Jun</month>
            <volume>69</volume>
            <issue>6</issue>
            <fpage>1239</fpage>
            <page-range>1239-42</page-range>
            <pub-id pub-id-type="pmid">19556211</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r119">
          <label>119</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Atzeni</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Masala</surname>
                <given-names>IF</given-names>
              </name>
              <name>
                <surname>di Franco</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sarzi-Puttini</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Infections in rheumatoid arthritis.</article-title>
            <source>Curr Opin Rheumatol</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>29</volume>
            <issue>4</issue>
            <fpage>323</fpage>
            <page-range>323-330</page-range>
            <pub-id pub-id-type="pmid">28422773</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r120">
          <label>120</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carbone</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bonaventura</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Liberale</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Paolino</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Torre</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dallegri</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Montecucco</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cutolo</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Atherosclerosis in Rheumatoid Arthritis: Promoters and Opponents.</article-title>
            <source>Clin Rev Allergy Immunol</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>58</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-14</page-range>
            <pub-id pub-id-type="pmid">30259381</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r121">
          <label>121</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nicolau</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lequerr&#x000e9;</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bacquet</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Vittecoq</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Rheumatoid arthritis, insulin resistance, and diabetes.</article-title>
            <source>Joint Bone Spine</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>84</volume>
            <issue>4</issue>
            <fpage>411</fpage>
            <page-range>411-416</page-range>
            <pub-id pub-id-type="pmid">27777170</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r122">
          <label>122</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Naranjo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sokka</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Descalzo</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Calvo-Al&#x000e9;n</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>H&#x000f8;rslev-Petersen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Luukkainen</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Combe</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Burmester</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Devlin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ferraccioli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Morelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hoekstra</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Majdan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sadkiewicz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Belmonte</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Holmqvist</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Choy</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tunc</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dimic</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bergman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Toloza</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pincus</surname>
                <given-names>T</given-names>
              </name>
              <collab>QUEST-RA Group</collab>
            </person-group>
            <article-title>Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study.</article-title>
            <source>Arthritis Res Ther</source>
            <year>2008</year>
            <volume>10</volume>
            <issue>2</issue>
            <fpage>R30</fpage>
            <pub-id pub-id-type="pmid">18325087</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r123">
          <label>123</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ozen</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pedro</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Michaud</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>The Risk of Cardiovascular Events Associated With Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis.</article-title>
            <source>J Rheumatol</source>
            <year>2021</year>
            <month>May</month>
            <volume>48</volume>
            <issue>5</issue>
            <fpage>648</fpage>
            <page-range>648-655</page-range>
            <pub-id pub-id-type="pmid">32801134</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r124">
          <label>124</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xie</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Yun</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Levitan</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Curtis</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Benefits of Methotrexate Use on Cardiovascular Disease Risk Among Rheumatoid Arthritis Patients Initiating Biologic Disease-modifying Antirheumatic Drugs.</article-title>
            <source>J Rheumatol</source>
            <year>2021</year>
            <month>Jun</month>
            <volume>48</volume>
            <issue>6</issue>
            <fpage>804</fpage>
            <page-range>804-812</page-range>
            <pub-id pub-id-type="pmid">33060309</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r125">
          <label>125</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Klein</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Polliack</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gafter-Gvili</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Rheumatoid arthritis and lymphoma: Incidence, pathogenesis, biology, and outcome.</article-title>
            <source>Hematol Oncol</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>36</volume>
            <issue>5</issue>
            <fpage>733</fpage>
            <page-range>733-739</page-range>
            <pub-id pub-id-type="pmid">29862535</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r126">
          <label>126</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baecklund</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Iliadou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Askling</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ekbom</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Backlin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Granath</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Catrina</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Rosenquist</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Feltelius</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sundstr&#x000f6;m</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Klareskog</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis.</article-title>
            <source>Arthritis Rheum</source>
            <year>2006</year>
            <month>Mar</month>
            <volume>54</volume>
            <issue>3</issue>
            <fpage>692</fpage>
            <page-range>692-701</page-range>
            <pub-id pub-id-type="pmid">16508929</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r127">
          <label>127</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hellgren</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Baecklund</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Backlin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sundstrom</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Smedby</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Askling</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Rheumatoid Arthritis and Risk of Malignant Lymphoma: Is the Risk Still Increased?</article-title>
            <source>Arthritis Rheumatol</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>69</volume>
            <issue>4</issue>
            <fpage>700</fpage>
            <page-range>700-708</page-range>
            <pub-id pub-id-type="pmid">27992692</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r128">
          <label>128</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hsieh</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zeng</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Incidence of fractures among patients with rheumatoid arthritis: a systematic review and meta-analysis.</article-title>
            <source>Osteoporos Int</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>29</volume>
            <issue>6</issue>
            <fpage>1263</fpage>
            <page-range>1263-1275</page-range>
            <pub-id pub-id-type="pmid">29546507</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r129">
          <label>129</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Schneeweiss</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Solomon</surname>
                <given-names>DH</given-names>
              </name>
            </person-group>
            <article-title>Risk of venous thromboembolism in patients with rheumatoid arthritis.</article-title>
            <source>Arthritis Care Res (Hoboken)</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>65</volume>
            <issue>10</issue>
            <fpage>1600</fpage>
            <page-range>1600-7</page-range>
            <pub-id pub-id-type="pmid">23666917</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r130">
          <label>130</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bacani</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Gabriel</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Crowson</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Heit</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Matteson</surname>
                <given-names>EL</given-names>
              </name>
            </person-group>
            <article-title>Noncardiac vascular disease in rheumatoid arthritis: increase in venous thromboembolic events?</article-title>
            <source>Arthritis Rheum</source>
            <year>2012</year>
            <month>Jan</month>
            <volume>64</volume>
            <issue>1</issue>
            <fpage>53</fpage>
            <page-range>53-61</page-range>
            <pub-id pub-id-type="pmid">21905005</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r131">
          <label>131</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Danwada</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Curtis</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Kilpatrick</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Hendrickson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Islam</surname>
                <given-names>SS</given-names>
              </name>
            </person-group>
            <article-title>Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the association with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world setting.</article-title>
            <source>RMD Open</source>
            <year>2019</year>
            <volume>5</volume>
            <issue>2</issue>
            <fpage>e001013</fpage>
            <pub-id pub-id-type="pmid">31673413</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r132">
          <label>132</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Matcham</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rayner</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Steer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hotopf</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis.</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>2013</year>
            <month>Dec</month>
            <volume>52</volume>
            <issue>12</issue>
            <fpage>2136</fpage>
            <page-range>2136-48</page-range>
            <pub-id pub-id-type="pmid">24003249</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r133">
          <label>133</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mu&#x000f1;oz-Fern&#x000e1;ndez</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ot&#x000f3;n-S&#x000e1;nchez</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Carmona</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Calvo-Al&#x000e9;n</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Escudero</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Narv&#x000e1;ez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez Heredia</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Romero Yuste</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vela</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Luj&#x000e1;n Vald&#x000e9;s</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Royo Garc&#x000ed;a</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Baquero</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Use of prognostic factors of rheumatoid arthritis in clinical practice and perception of their predictive capacity before and after exposure to evidence.</article-title>
            <source>Rheumatol Int</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>38</volume>
            <issue>12</issue>
            <fpage>2289</fpage>
            <page-range>2289-2296</page-range>
            <pub-id pub-id-type="pmid">30251128</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17856.r134">
          <label>134</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Solomon</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Katz</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Bitton</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Corrigan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fraenkel</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Harrold</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Smolen</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Losina</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Adverse Events and Resource Use Before and After Treat-to-Target in Rheumatoid Arthritis: A Post Hoc Analysis of a Randomized Controlled Trial.</article-title>
            <source>Arthritis Care Res (Hoboken)</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>71</volume>
            <issue>9</issue>
            <fpage>1243</fpage>
            <page-range>1243-1248</page-range>
            <pub-id pub-id-type="pmid">30221841</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
